[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1454
1. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH: Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol; 2007 Jan;62(1):28-34; discussion 35-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis.
  • AIM: To evaluate patterns of disease and identify factors predicting outcome in patients presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • MATERIALS AND METHODS: A retrospective review was performed of the imaging and clinical data in 86 patients (median age 66 years, range 42-88 years) presenting with recurrent endometrial adenocarcinoma following primary surgery.
  • RESULTS: Following primary surgery recurrent disease occurred within 2 years in 64% and within 3 years in 87%.
  • Univariate survival analysis showed the factors significant for poor outcome were: multiple sites of disease, liver and splenic disease, haematogenous, peritoneal and nodal spread, poorly differentiated tumour, and early relapse.
  • Multivariate analysis identified multiple sites of disease, liver and splenic metastases to be independent predictors of poor outcome.
  • Significant predictors of poor outcome in recurrent disease are multiple sites of disease and liver and splenic metastases.
  • [MeSH-major] Adenocarcinoma / radiography. Endometrial Neoplasms / radiography. Neoplasm Recurrence, Local / radiography. Neoplasms, Multiple Primary / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hysterectomy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Staging. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / secondary. Prognosis. Retrospective Studies. Splenic Neoplasms / radiography. Splenic Neoplasms / secondary. Vaginal Neoplasms / radiography. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145260.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR: High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol; 2009 Jan;50(1):158-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High lifetime risk of cancer in primary sclerosing cholangitis.
  • BACKGROUND/AIMS: Primary sclerosing cholangitis (PSC) patients are at risk for developing cholangiocarcinoma (CCA) and colorectal carcinoma (CRC).
  • CCA, cholangitis, and age at entry were independent risk factors for the combined endpoint death or liver transplantation.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Inflammatory Bowel Diseases / complications. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Factors. Young Adult


3. Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, Tanaka K, Togo S, Ohki S, Shimada H: Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res; 2008 Apr 15;14(8):2351-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer.
  • The aim of this study was to determine the AR, EGFR, and HER2 protein expression levels and to evaluate their prognostic relevance to the clinical course of colorectal cancer.
  • EXPERIMENTAL DESIGN: The AR, EGFR, and HER2 protein levels in primary tumors of colorectal cancer (n = 106) were examined using immunohistochemistry.
  • Metastatic sites in liver specimens (n = 16) were also analyzed in the same manner.
  • RESULTS: Thirteen (81.6%) metastatic lesions of the liver stained positive for AR.
  • Among the primary lesions of colorectal cancer, 58 (54.7%) stained positive for AR, 13 (12.3%) stained positive for EGFR, and 5 (4.7%) stained positive for HER2.
  • When the relationships between each protein expression level and the clinicopathologic factors were examined, only the AR expression level was significantly related to liver metastasis (P = 0.0296).
  • A multivariate analysis of liver metastasis proved that AR expression was an independent prognostic factor of liver metastasis from colorectal cancer (P = 0.0217).
  • CONCLUSIONS: AR expression in primary lesions of colorectal cancer is an important predictive marker of liver metastasis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. Glycoproteins / analysis. Intercellular Signaling Peptides and Proteins / analysis. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amphiregulin. EGF Family of Proteins. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis


Advertisement
4. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer; 2008;8:351
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
  • We studied 32 HCC lesions, where 23 lesions (22 patients) were treated targeting small non-resectable primary HCC, and 9 lesions (9 patients) targeting PVTT using the Cyberknife.
  • CONCLUSION: SBRT for small HCC and SBRT combined with TACE for advanced HCC with PVTT showed feasible treatment modalities with minimal side effects in selected patients with primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / surgery. Liver Neoplasms / therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):81-7 [10924975.001]
  • [Cites] Hepatology. 2008 Jan;47(1):71-81 [18027884.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):164-70 [11134209.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):149-58 [11369526.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):660-5 [11422619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):522-31 [11872300.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1609-19 [12016426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5 [12182985.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):113-9 [12909223.001]
  • [Cites] Radiology. 1983 Aug;148(2):397-401 [6306721.001]
  • [Cites] Radiother Oncol. 1983 Nov;1(2):187-91 [6680223.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1425-34 [1938550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1249-56 [7713786.001]
  • [Cites] Scand J Gastroenterol. 1997 Jun;32(6):598-603 [9200294.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3 [16168826.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):273-8 [16183481.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7391-400 [16437707.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):154-8 [16520355.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1653-63 [16541431.001]
  • [Cites] Acta Oncol. 2006;45(7):961-5 [16982564.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):938-46 [17350942.001]
  • [Cites] J Am Coll Radiol. 2007 Aug;4(8):563-5 [17660122.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1187-95 [11072178.001]
  • (PMID = 19038025.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615783
  •  go-up   go-down


5. Somi MH, Farhang S, Mirinezhad SK, Naghashi S, Seif-Farshad M, Golzari M: Cancer in East Azerbaijan, Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer in East Azerbaijan, Iran: results of a population-based cancer registry.
  • BACKGROUND AND AIMS: Regardless of the fact that cancers of GI tract have been reported to be the most common fatal neoplasms in East Azerbaijan, there is a serious lack of population-based studies in this region.
  • METHODS: A comprehensive search was therefore undertaken to prospectively register all cases of cancer occurring in the province during March 2006-2007.
  • Diagnosis of cancer was based on histopathology of primary lesions in 84.0% of cases, clinical investigation and ultrasound in 7.2%, only clinical investigation in 5.4%, and histology of metastasis in 2.9.
  • RESULTS: A total of 4,922 cancers (mean age 60.2+18.13 years) were diagnosed during this population-based study.
  • ASRs for all cancers in males and females were 164.3 and 130.6 respectively.
  • The top five sites for cancer in males (excluding skin cancer) according to the calculated ASR (world) were stomach (26.0), bladder (15.7), esophagus (12.4), colon and rectum (11.6) and blood (10.8); in females, they were breast (23.5), esophagus (11.7), stomach (11.6), colon and rectum (9.7) and nervous system (5.5).
  • CONCLUSION: This first comprehensive report on cancer incidence in East Azerbaijan, documents particularly high incidence rates for esophageal and gastric cancer across the sexes.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Iran / epidemiology. Male. Middle Aged. Prospective Studies. Sex Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712985.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


6. Wang W, Peng JX, Yang JQ, Yang LY: Identification of gene expression profiling in hepatocellular carcinoma using cDNA microarrays. Dig Dis Sci; 2009 Dec;54(12):2729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differentially expressed genes between 22 fresh HCC tissues and para-cancerous liver tissues (PCLT) were displayed using cDNA microarray technology.
  • This study describes a gene expression profiling of HCC, which provides an extensive list of potential molecular markers for early diagnosis and molecular targets for the development of drugs to treat patients with primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adult. Aged. Cadherins / genetics. China. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. rho GTP-Binding Proteins / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Springer Science+Business Media, LLC 2008
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):861-70 [12808121.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1139-48 [12117771.001]
  • [Cites] Nat Genet. 2006 Jan;38(1):101-6 [16341224.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):497-506 [15542433.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2280-8 [11710894.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):665-72 [16423995.001]
  • [Cites] Lancet. 1997 May 3;349(9061):1269-76 [9142060.001]
  • [Cites] Br J Cancer. 1998;77(1):147-52 [9459160.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):925-30 [15999367.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1319-31 [9782009.001]
  • [Cites] J Surg Res. 2003 Aug;113(2):208-16 [12957131.001]
  • [Cites] J Biomed Sci. 2003;10(6 Pt 1):625-35 [14576465.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S173-81 [16447285.001]
  • [Cites] Oncogene. 2005 May 26;24(23):3737-47 [15735714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9668-73 [12902543.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2349-55 [15150600.001]
  • [Cites] Bioessays. 1996 May;18(5):427-31 [8639166.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1950-3 [12970882.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12 ):3043-8 [12810624.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jul;128(7):369-79 [12136251.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Nov;24(6):564-6 [12667326.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • (PMID = 19117127.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / PCLKC protein, human; 0 / RHOC protein, human; 0 / RNA, Messenger; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


7. Wang FH, Li YH, Li S, Jiang WQ, Guan ZZ: [Phase I clinical trial of intravenous recombinant human lymphotoxin-alpha derivative]. Ai Zheng; 2006 Apr;25(4):501-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No obvious abnormity of liver and renal functions was observed.
  • Although there was no definite efficacy showed in this primary study, initial response to rhLTalpha-Da was seen on a minority of patients with cancers, including malignant melanoma, mycosis fungoides, and renal carcinoma.
  • [MeSH-minor] Adult. Aged. Chills / chemically induced. Dose-Response Relationship, Drug. Dyspnea / chemically induced. Female. Fever / chemically induced. Humans. Male. Maximum Tolerated Dose. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613689.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase I; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lymphotoxin-alpha; 0 / Recombinant Proteins
  •  go-up   go-down


8. Lu PX, Wang JB, Zhang QN, Wu Y, Sun Y, Chen TY: [Longitudinal study of aflatoxin exposure in the development of primary liver cancer in patients with chronic hepatitis]. Zhonghua Yi Xue Za Zhi; 2010 Jun 22;90(24):1665-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Longitudinal study of aflatoxin exposure in the development of primary liver cancer in patients with chronic hepatitis].
  • OBJECTIVE: To study the relationship between aflatoxin exposure and the development of primary liver cancer (PLC) in patients with chronic hepatitis.
  • The urine excretion of AFM1 was also obviously related with the abnormal liver function (P = 0.035).
  • 96/100 000) significantly higher than that of cohort people (P = 0.001) and the same natural peoples (P = 0.000, RR = 15.09). (6) It took an average time of 14.65 years (median 13.68) from hepatitis occurrence to PLC diagnosis and 7.38 years (median 6.40) from liver cirrhosis to PLC diagnosis.
  • [MeSH-major] Aflatoxins / adverse effects. Environmental Exposure. Hepatitis B, Chronic / complications. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Carrier State. Humans. Incidence. Longitudinal Studies. Male. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979873.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Aflatoxins
  •  go-up   go-down


9. Li XW, Gong SJ, Song WH, Zhu JJ, Pan CH, Wu MC, Xu AM: Undifferentiated liver embryonal sarcoma in adults: a report of four cases and literature review. World J Gastroenterol; 2010 Oct 7;16(37):4725-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated liver embryonal sarcoma in adults: a report of four cases and literature review.
  • AIM: To evaluate the undifferentiated embryonal sarcoma of liver (UESL) in adults in order to improve its diagnosis and treatment.
  • METHODS: Four primary and one recurrent cases of UESL were clinicopathologically evaluated and immunohistochemically investigated with a panel of antibodies using the EnVision+ system.
  • [MeSH-major] Liver Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Differentiation. Child. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Embryonal Sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Dev Pathol. 2001 Sep-Oct;4(5):482-9 [11779051.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(5):536-44 [18836810.001]
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1419-23 [12378446.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):246-52 [12673559.001]
  • [Cites] Endoscopy. 1977 May;8(2):108-10 [140795.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):121-3 [72700.001]
  • [Cites] Cancer. 1978 Jul;42(1):336-48 [208754.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1510-7 [6681727.001]
  • [Cites] Histopathology. 1983 Jan;7(1):113-21 [6840705.001]
  • [Cites] Pediatr Pathol. 1983 Jul-Sep;1(3):281-90 [6687281.001]
  • [Cites] Gut. 1987 Jun;28(6):668-74 [3623214.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):1-16 [1702267.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):319-21 [1427575.001]
  • [Cites] Ann Clin Lab Sci. 1994 Nov-Dec;24(6):495-500 [7847778.001]
  • [Cites] Curr Top Pathol. 1995;89:261-72 [7882713.001]
  • [Cites] Am Surg. 1996 Nov;62(11):901-6 [8895710.001]
  • [Cites] Radiology. 1997 Jun;203(3):779-83 [9169704.001]
  • [Cites] J Hepatol. 2005 Mar;42(3):424-9 [15710230.001]
  • [Cites] Arch Pathol Lab Med. 2006 Feb;130(2):e24-6 [16454576.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):193-7 [16785789.001]
  • [Cites] World J Gastroenterol. 2008 Dec 21;14(47):7267-70 [19084947.001]
  • [Cites] J Dig Dis. 2009 Nov;10(4):305-9 [19906110.001]
  • [Cites] Chin Med J (Engl). 2010 Jan 20;123(2):250-2 [20137381.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):195-8 [19809302.001]
  • [Cites] Ultrastruct Pathol. 2006 Nov-Dec;30(6):403-8 [17182431.001]
  • [Cites] J Gastrointest Surg. 2007 Jan;11(1):73-5 [17390190.001]
  • [Cites] Histopathology. 2007 Aug;51(2):195-203 [17573940.001]
  • [Cites] Cancer. 2008 May 15;112(10):2274-82 [18361435.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):252-7 [11815984.001]
  • (PMID = 20872975.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2951525
  •  go-up   go-down


10. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, Blumgart L, Jarnagin W, Larson SM, Fong Y: Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol; 2005 Dec 1;23(34):8713-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: [18F]2-fluoro-2-deoxyglucose (FDG) -positron emission tomography (PET) has become a useful tool in the assessment of patients with colorectal cancer.
  • Patients often undergo chemotherapy as treatment for primary or metastatic colorectal malignancy.
  • Pathologic analysis of the liver resection specimens was used as gold standard.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / therapy. Fluorodeoxyglucose F18. Fluorouracil / therapeutic use. Liver Neoplasms / diagnosis. Positron-Emission Tomography / standards
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Liver / drug effects. Liver / radionuclide imaging. Liver / surgery. Male. Middle Aged. Multivariate Analysis. Prospective Studies. Regression Analysis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314631.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA61524; United States / NCI NIH HHS / CA / R01CA72632; United States / NCI NIH HHS / CA / R01CA76416; United States / NCI NIH HHS / CA / R01CA80982
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0Z5B2CJX4D / Fluorodeoxyglucose F18; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Chen JG, Lu JH, Zhu YR, Zhu J, Zhang YH: [A thirty-one year prospective follow-up program on the HBsAg carrier state and primary liver cancer in Qidong, China]. Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Jul;31(7):721-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A thirty-one year prospective follow-up program on the HBsAg carrier state and primary liver cancer in Qidong, China].
  • OBJECTIVE: To study the relationship between hepatitis B virus (HBV) and primary liver cancer (PLC), and to assess the outcome of PLC in the carriers of HBsAg.
  • From January 1, 1977 through December 31, 2007, 12 351 people were enrolled in the cohort, and their occurrence, outcome of PLC and other cancers, together with all the withdrawals due to death were linked to and checked with database from Qidong Cancer Registry and Qidong Vital Registry programs.
  • No relationship was found among carriers and non-carriers for cancer sites such as lung, stomach, esophagus, intestine, pancreas, breast, cervix, bladder, and lymphoma, brain tumor, or leukemia.
  • [MeSH-major] Hepatitis B virus. Liver Neoplasms / epidemiology. Liver Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State. Causality. China / epidemiology. Female. Follow-Up Studies. Hepatitis B Surface Antigens. Humans. Incidence. Male. Middle Aged. Prospective Studies. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21162830.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


12. Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF: Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol; 2008 Aug;67(2):336-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine potential factors were found with significant effects on survival rate, and they were number of tumors, location of tumors, pre-RFA liver function enzymes, Child-Pugh classification, AJCC staging, primary or recurrent HCC, tumor pathological grading, using mathematical protocol in RFA procedure and tumor necrosis 1 month after RFA.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765421.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


13. Lai MS, Hsieh MS, Chiu YH, Chen TH: Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology; 2006 Jun;43(6):1295-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to elucidate the relationship of type 2 diabetes, other known risk factors, and primary hepatocellular carcinoma (HCC) in countries with a high prevalence of hepatitis infection.
  • A total of 5,732 subjects with type 2 diabetes cases were identified at enrollment on the basis of fasting blood glucose level, and a total of 138 confirmed HCC cases were identified either through two-stage liver cancer screening or linkage with the National Cancer Registry.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Diabetes Mellitus, Type 2 / epidemiology. Hepatitis C, Chronic / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Comorbidity. Endemic Diseases. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prevalence. Probability. Proportional Hazards Models. Prospective Studies. Severity of Illness Index. Sex Distribution. Survival Rate. Taiwan / epidemiology


14. Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff JC, Bohrer MH, Riemann JF: [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site]. Dtsch Med Wochenschr; 2007 Feb 23;132(8):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site].
  • BACKGROUND AND OBJECTIVE: The diagnostic approach to newly detected space-occupying lesions in the liver can be difficult and a histogenetic classification of the primary tumor is impossible in some cases.
  • Such cases of metastatic disease without a detectable primary tumor are classified as cancer of unknown primary site (CUP).
  • It was the main aim of this study to analyze the true incidence of adenocarcinoma metastases of the liver with an unknown primary cancer after application of a standardized protocol of clinical and immunhistochemical diagnostic tests and a long-term follow-up.
  • PATIENTS AND METHODS: Between January 2000 and January 2003 127 consecutive patients underwent diagnostic ultrasound-guided biopsy of a space-occupying lesion in the liver.
  • Primary tumors of the liver were found in 21 cases and non-hepatocellular tumors (metastases) were documented in 106 patients, 82 of the latter (77%) had metastases of an adenocarcinoma.
  • The further diagnostic approach was based on histochemistry, immunhistochemistry and imaging techniques, making possible a full diagnosis of primary tumor in a further 59 (72%) cases.
  • Thus the incidence of an adenocarcinoma of the liver of unknown primary site was 23 of 127 cases (18%).
  • [MeSH-major] Adenocarcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Incidence. Karnofsky Performance Status. Liver / pathology. Liver / ultrasonography. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299675.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Sun YL, Yin SY, Xie HY, Zhou L, Xue F, Wu LM, Gao F, Zheng SS: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepatocellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 1):1280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Recent investigations demonstrate that adult stem cells may be targets for malignant transformation and that the stem-like cells in diseased livers possess the capacity of tumorigenicity in animal models.
  • METHODS: Twenty surgically resected HCCs and corresponding adjacent tissues as well as 10 cirrhotic liver tissues were collected and immunohistochemical staining were performed to detect the expression of CD34, Thy-1, CD133, and c-kit.
  • Then the non-cancerous tissues were transplanted into immunodeficient mice and the characteristics of the cells from primary tissue cultures were explored in vitro.
  • CONCLUSION: Our results suggest that the stem-like cells in cirrhotic livers possess the capacity of tumorigenicity and may contain candidates for HCC cancer stem cells.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Hepatitis B, Chronic / complications. Liver Cirrhosis / metabolism. Liver Neoplasms / metabolism. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466286.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Nakayama N, Tanabe S, Koizumi W, Higuchi K, Sasaki T, Nakatani K, Shimoda T, Nishimura K, Kobayashi N, Mitomi H, Saigenji K: [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
  • Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy.
  • Subsequently, abdominal computed tomography showed lymph-node swelling, multiple metastases to the liver, ascites, and a right pleural effusion.
  • Chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin may thus be an effective therapeutic option in patients who have advanced gastric cancer with peritoneal dissemination.
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Hysterectomy. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Methotrexate / administration & dosage. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Pancreatectomy. Survivors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Kim KO, Lee HY, Chun SH, Shin SJ, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM: Clinical overview of extrapulmonary small cell carcinoma. J Korean Med Sci; 2006 Oct;21(5):833-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary sites of tumor were the esophagus and thymus in 6 patients (17.6%) each, pancreas and stomach in 5 patients each (14.7%); other sites included were the cervix, abdominal lymph nodes, abdominal wall, bladder, colon, maxillary sinus, nasal cavity, ovary, parotid gland and liver.
  • Independent prognostic factors included stage and primary tumor location.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Esophageal Neoplasms / mortality. Esophageal Neoplasms / therapy. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / therapy. Survival Rate. Thymus Neoplasms / mortality. Thymus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):262-7 [10640955.001]
  • [Cites] Semin Respir Crit Care Med. 2005 Jun;26(3):333-41 [16052435.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1436-41 [12627507.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):274-7 [12908782.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):250-4 [15231859.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):123-36 [7064914.001]
  • [Cites] Semin Oncol. 1982 Dec;9(4):484-96 [6302908.001]
  • [Cites] Hum Pathol. 1987 Jan;18(1):9-21 [2434408.001]
  • [Cites] Am J Gastroenterol. 1987 Apr;82(4):382-5 [3031980.001]
  • [Cites] Medicine (Baltimore). 1987 Nov;66(6):457-71 [2824968.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1531-3 [2550125.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):89-99 [1310345.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):909-13 [7696162.001]
  • [Cites] Acta Oncol. 1997;36(1):78-80 [9090972.001]
  • [Cites] Cancer. 1997 May 1;79(9):1729-36 [9128989.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] South Med J. 2005 Mar;98(3):345-9 [15813162.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):295-300 [15823115.001]
  • [Cites] Neth J Med. 2000 Feb;56(2):51-5 [10710941.001]
  • (PMID = 17043415.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2721992
  •  go-up   go-down


18. Harzke AJ, Baillargeon J, Paar DP, Pulvino J, Murray OJ: Chronic liver disease mortality among male prison inmates in Texas, 1989-2003. Am J Gastroenterol; 2009 Jun;104(6):1412-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic liver disease mortality among male prison inmates in Texas, 1989-2003.
  • OBJECTIVES: Alcohol abuse and chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the major etiologic factors for chronic liver disease/cirrhosis (CLD) in the United States.
  • These CLD risk factors are highly prevalent in US adult incarcerated populations, but CLD-related mortality data from these populations are lacking.
  • The primary objective of this study was to assess CLD-related mortality over time and across categories of race-ethnicity from 1989 through 2003 among male inmates in the Texas state prison system.

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Feb;39(2):476-83 [14768001.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Prev Med. 2004 May;38(5):607-12 [15066363.001]
  • [Cites] Am J Public Health. 2004 Jul;94(7):1218-23 [15226146.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):423-4 [15280325.001]
  • [Cites] Am J Epidemiol. 1975 Oct;102(4):267-71 [1180251.001]
  • [Cites] Am J Epidemiol. 1986 Aug;124(2):161-79 [3524199.001]
  • [Cites] Am J Drug Alcohol Abuse. 1988;14(3):293-308 [3189253.001]
  • [Cites] Am J Public Health. 1989 May;79(5):563-4 [2705587.001]
  • [Cites] Am J Epidemiol. 1990 Feb;131(2):373-5 [2296988.001]
  • [Cites] Epidemiology. 1996 Jan;7(1):29-33 [8664397.001]
  • [Cites] Gastroenterologist. 1997 Mar;5(1):58-77 [9074920.001]
  • [Cites] Am J Epidemiol. 1997 Oct 1;146(7):565-71 [9326434.001]
  • [Cites] MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39 [9790221.001]
  • [Cites] Alcohol Health Res World. 1998;22(4):265-9 [15706753.001]
  • [Cites] Am J Public Health. 2005 Apr;95(4):696-702 [15798132.001]
  • [Cites] Am J Public Health. 2005 May;95(5):887-93 [15855470.001]
  • [Cites] Clin Infect Dis. 2005 Jul 15;41(2):177-86 [15983913.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2186-93 [16181367.001]
  • [Cites] Am J Public Health. 2005 Oct;95(10):1793-9 [16186457.001]
  • [Cites] Addiction. 2006 Feb;101(2):181-91 [16445547.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Ann Epidemiol. 2007 Oct;17(10):808-13 [17689260.001]
  • [Cites] J Clin Gastroenterol. 2007 Oct;41(9):859-62 [17881933.001]
  • [Cites] Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 [18512336.001]
  • [Cites] Am J Gastroenterol. 2008 Sep;103(9):2231-8 [18671818.001]
  • [Cites] Hepatology. 2008 Nov;48(5):1387-95 [18924228.001]
  • [Cites] Public Health Rep. 2009 Jan-Feb;124(1):120-6 [19413034.001]
  • [Cites] Hepatology. 2000 Mar;31(3):777-82 [10706572.001]
  • [Cites] J Stud Alcohol. 2000 Mar;61(2):301-10 [10757141.001]
  • [Cites] Hum Biol. 2000 Oct;72(5):801-20 [11126726.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):102-5 [11743583.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):916-25 [12072545.001]
  • [Cites] Am J Public Health. 2002 Nov;92(11):1789-94 [12406810.001]
  • [Cites] MMWR Recomm Rep. 2003 Jan 24;52(RR-1):1-36; quiz CE1-4 [12562146.001]
  • [Cites] JAMA. 2003 Jun 4;289(21):2849-56 [12783916.001]
  • [Cites] Public Health. 2003 Jan;117(1):43-8 [12802904.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):960-7 [12809815.001]
  • [Cites] JAMA. 2003 Jul 9;290(2):228-37 [12851278.001]
  • [Cites] J Urban Health. 2004 Mar;81(1):25-37 [15047781.001]
  • (PMID = 19491854.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057712-14; United States / NCI NIH HHS / CA / R25 CA057712; United States / NCI NIH HHS / CA / R25 CA 57712; United States / NCI NIH HHS / CA / R25 CA057712-14
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS190518; NLM/ PMC2856927
  •  go-up   go-down


19. Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK, Hawkins WG, Siegel BA, Delbeke D, Pinson CW, Strasberg SM: A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables. J Am Coll Surg; 2008 May;206(5):857-68; discussion 868-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
  • BACKGROUND: The purpose of this study was to develop a prognostic system applicable to patients with hepatic metastasis from colorectal cancer in whom extrahepatic disease was excluded by preoperative PET with [(18)F]fluoro-2-deoxy-D-glucose (FDG-PET).
  • STUDY DESIGN: Data were analyzed for 285 consecutive patients undergoing liver resection for colorectal metastases from 1995 to 2005 at 2 institutions routinely using preoperative FDG-PET with.
  • Fifteen clinicopathologic variables of the primary and secondary tumors were examined to identify factors predictive of survival.
  • In this subgroup, positive lymph node status in the primary colorectal tumor resection specimen was the only characteristic that predicted survival of patients in both institutions.
  • CONCLUSIONS: In patients with colorectal liver metastases staged with FDG-PET with overall survival can be predicted directly from data in the pathology report of the colorectal primary tumor.
  • [MeSH-major] Colorectal Neoplasms / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Viloxazine

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471711.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5I5Y2789ZF / Viloxazine
  •  go-up   go-down


20. Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg; 2006 Jul;82(1):254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer.
  • BACKGROUND: Treatment of pulmonary metastases from colorectal cancer by excision has increased rapidly, but reports on indications and prognostic factors are inconsistent.
  • METHODS: A total of 75 patients with colorectal cancer had pulmonary metastases excised from 1986 to 2003.
  • Tumor size, number, laterality, hilar or mediastinal lymphadenopathy, and carcinoembryonic antigen level were possible risk factors for metastatic tumors, with primary site of colorectal tumor, disease-free interval, and hepatectomy for liver metastasis possible risk factors for primary tumors.
  • RESULTS: Five-year survival rates were 41.3% after pulmonary excision and 73.1% after primary colorectal resection.
  • In contrast, carcinoembryonic antigen, number of metastases, and disease-free interval predicted prognosis after primary colorectal resection.
  • CONCLUSIONS: Elevated carcinoembryonic antigen level and multiple metastases are preoperative predictors of poor prognosis after resection of pulmonary metastases from colorectal cancer.
  • Survival rate is sufficient to justify pulmonary metastasectomy if there is no local or distant metastatic lesion other than in the liver; if needed, sequential pulmonary and hepatic metastasectomy can be performed.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / analysis. Disease-Free Survival. Female. Follow-Up Studies. Hepatectomy. Humans. Life Tables. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sex Factors. Survival Analysis. Tumor Burden

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798225.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


21. Akaraviputh T, Arunakul S, Lohsiriwat V, Iramaneerat C, Trakarnsanga A: Surgery for gastrointestinal malignant melanoma: experience from surgical training center. World J Gastroenterol; 2010 Feb 14;16(6):745-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Fourteen patients had GI involvement either in a metastatic form or as a primary melanoma.
  • Seven patients had primary melanomas of the anal canal, stomach and the sigmoid colon (5, 1 and 1 cases, respectively).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies. Thailand. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1614-21 [10764421.001]
  • [Cites] Clin Nucl Med. 2009 Jul;34(7):483-5 [19542966.001]
  • [Cites] J Med Assoc Thai. 1978 Apr;61(4):210-6 [650113.001]
  • [Cites] Br J Cancer. 1979 Aug;40(2):185-93 [475965.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):60-1 [1689196.001]
  • [Cites] Ann Surg Oncol. 1999 Mar;6(2):155-60 [10082040.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Cancer. 1964 Oct;17:1323-39 [14236766.001]
  • [Cites] J Med Assoc Thai. 2005 Aug;88(8):1128-33 [16404844.001]
  • [Cites] Mayo Clin Proc. 2006 Apr;81(4):511-6 [16610571.001]
  • [Cites] Am J Surg. 2008 Sep;196(3):e1-2 [18513686.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E6-7 [18278714.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E30-1 [18278719.001]
  • [Cites] Int J Colorectal Dis. 2008 Dec;23(12):1257-62 [18633625.001]
  • [Cites] Dig Liver Dis. 2009 Feb;41(2):169 [18619931.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):313-9 [18590949.001]
  • [Cites] J Gastroenterol Hepatol. 2009 Apr;24(4):697 [19368636.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):516-21 [19410196.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • (PMID = 20135724.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2817064
  •  go-up   go-down


22. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol; 2005 Nov;174(5):1759-63; discussion 1763
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC).
  • A scoring algorithm to predict cancer specific survival was developed using the regression coefficients from a Cox proportional hazards model.
  • Constitutional symptoms at nephrectomy (+2), metastases to the bone (+2) or liver (+4), metastases in multiple simultaneous sites (+2), metastases at nephrectomy (+1) or within 2 years of nephrectomy (+3), complete resection of all metastatic sites (-5), tumor thrombus level I to IV (+3), and the primary pathological features of nuclear grade 4 (+3) and histological tumor necrosis (+2) were significantly associated with death from RCC.
  • Cancer specific survival rates at 1 year were 85.1%, 72.1%, 58.8%, 39.0%, and 25.1%, respectively, for patients with scores of -5 to -1, scores of 0 to 2, scores of 3 to 6, scores of 7 or 8, and scores of 9 or more.
  • CONCLUSIONS: This scoring algorithm can be used to predict cancer specific survival for patients with metastatic clear cell RCC.
  • [MeSH-minor] Adult. Age Distribution. Aged. Clinical Trials as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Nephrectomy / methods. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis


23. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • AIM: To assess subcellular localization of KL-6 mucin and its clinicopathological significance in colorectal carcinoma as well as metastatic lymph node and liver tissues.
  • METHODS: Colorectal carcinoma tissues as well as metastatic lymph node and liver tissues were collected from 82 patients who underwent colorectomy or hepatectomy.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • Positive staining was observed in all metastatic lesions tested as well as in the primary colorectal carcinoma tissues.
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Mucin-1. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


24. Bornhak S, Heidemann E, Herschlein HJ, Simon W, Merkle E, Widmaier G, Ernst R, Greulich M, Bittner R, Kieninger G, Merkle P, Strosche H, Karg C, Wellhaeusser U, Aulitzky W, Schmidt B, Metzger H, Hahn M, Stauch A, Meisner C, Selbmann HK, Regelmann C, Brinkmann F: Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study. Onkologie; 2007 Sep;30(8-9):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study.
  • BACKGROUND: The homogeneity of the schemes for follow-up care after curative surgical treatment of early breast cancer is still a matter of debate in Germany.
  • PATIENTS AND METHODS: In a prospective, non-randomised, multicentre cohort study carried out between 1995 and 2000, 244 patients underwent a conventional follow-up (scheduled laboratory tests including CEA and CA 15-3, chest X-rays and liver ultrasound).
  • CONCLUSION: The results confirm that regular imaging and laboratory tests have no relevant effect on overall survival of patients after curative primary therapy of early breast cancer and support the implementation of a symptom-oriented routine follow-up.
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Reproducibility of Results. Risk Factors. Sensitivity and Specificity. Survival Analysis. Survival Rate. Treatment Outcome


25. Lee JM, Wong CM, Ng IO: Hepatitis B virus-associated multistep hepatocarcinogenesis: a stepwise increase in allelic alterations. Cancer Res; 2008 Jul 15;68(14):5988-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, there was no significant difference in FAL indices between primary HCCs and their corresponding intrahepatic metastases, but this absence of major allelic losses in this transformation to a metastatic phenotype does not exclude small-scale chromosomal losses or gene deletions.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / virology. Hepatitis B virus / metabolism. Liver Neoplasms / genetics. Liver Neoplasms / virology. Loss of Heterozygosity
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Fibrosis / genetics. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Mutation. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632655.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Li T, Li ZW, Wen HC: [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Dec;29(12):941-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
  • OBJECTIVE: To evaluate the efficacy and safety of high doses of thymopentin (10 mg/d) combined with transartery chemoembolization for primary liver cancer.
  • METHODS: Fifty primary liver cancer patients were randomly divided into two groups: therapeutic and control group, and all were treated with transfemoral artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5-Fu 750 mg, CF 300 mg and lipiodol 20 ml.
  • CONCLUSION: Transartery chemoembolization combined with high dose of thymopentin in the treatment for primary liver cancer is effective and safe, and can significantly improve the immune function and the chemotherapy tolerance.
  • [MeSH-major] Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Thymopentin / therapeutic use
  • [MeSH-minor] Adjuvants, Immunologic / adverse effects. Adjuvants, Immunologic / therapeutic use. Adult. Aged. Asthenia / chemically induced. CD4-Positive T-Lymphocytes. Combined Modality Therapy. Disease-Free Survival. Epirubicin / administration & dosage. Female. Fever / chemically induced. Fluorouracil / administration & dosage. Humans. Iodized Oil / administration & dosage. Lymphocyte Count. Male. Middle Aged. Nausea / chemically induced. Organoplatinum Compounds / administration & dosage. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478937.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; O3Y80ZF13F / Thymopentin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Shengbing Z, Feng LJ, Bin W, Lingyun G, Aimin H: Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anat Rec (Hoboken); 2009 Aug;292(8):1128-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KiSS-1 has been identified as a putative metastasis-suppressor gene in human melanomas and breast cancer cell lines.
  • Although loss of KiSS-1 expression has been associated with progression and poor prognosis of various cancers, the exact role of KiSS-1 expression in HCC is not well-defined.
  • The expression of KiSS-1 protein in HCC and intrahepatic metastasis lesions was significantly lower (P < 0.01) when compared with non-tumor liver tissue and normal liver tissue.
  • Loss of KiSS-1 in intrahepatic metastasis versus primary carcinomas was statistically significant (P<0.01).
  • [MeSH-major] Biomarkers, Tumor / physiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adult. Aged. Disease Progression. Down-Regulation. Female. Gene Expression. Humans. Kisspeptins. Male. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19645016.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Tumor Suppressor Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


28. Thomas H, Heaton ND: Late recurrence after surgery for cholangiocarcinoma: implications for follow-up? Hepatobiliary Pancreat Dis Int; 2008 Oct;7(5):544-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Biliary tract cancer is uncommon, but has a high rate of early recurrence and a poor prognosis.
  • RESULTS: Few long-term survivors with biliary tract cancer have been reported.
  • There is a need to differentiate a new primary and field change from recurrence of the previous tumor.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Biliary Tract Surgical Procedures. Bone Neoplasms / secondary. Cholangiocarcinoma / surgery. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Palliative Care. Radiotherapy, Adjuvant. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842505.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Zhu H, Chen XP, Zhang WG, Luo SF, Zhang BX: Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol; 2005 Jul 7;11(25):3855-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of survivin and vascular endothelial growth factor (VEGF) was investigated in 38 cases of HCC tissues and 38 liver cirrhosis tissues by immunohistochemistry and Western blot.
  • RESULTS: Survivin protein was detected in 23 (60.5%) of 38 HCCs and 3 (7.9%) of 38 liver cirrhosis tissues.
  • In liver cirrhosis tissues, the expression of VEGF was as follows: 24 cases were negative, 10 cases were weak positive and 4 cases were strong positive.
  • The expression of survivin in the primary lesion is very useful as an indicator for metastasis and prognosis of HCC.
  • [MeSH-major] Apoptosis. Carcinoma, Hepatocellular / physiopathology. Liver Neoplasms / physiopathology. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991282.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC4504885
  •  go-up   go-down


30. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M: Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat; 2008 Jun;109(3):417-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings.
  • PURPOSE: To describe the role of Positron Emission Tomography/Computed Tomography (PET/CT), Magnetic Resonance Imaging (MRI), sonography, and mammography in patients with inflammatory breast cancer (IBC).
  • A primary BPL was found in 60 patients (80%) on mammography (mass or calcifications), 72 (95%) on sonography (mass or architectural distortion), 23 (96%) on PET/CT (hypermetabolic BPL), and 33 (100%) on MRI (enhancing BPL).
  • Distant metastases in the bone, liver, and contralateral lymph nodes were diagnosed in nine patients (38%) on PET/CT.
  • CONCLUSION: MRI was the most accurate imaging technique in detecting a primary BPL in IBC patients.
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed


31. Tan WS, Ho KS, Eu KW: Brain metastases in colorectal cancers. World J Surg; 2009 Apr;33(4):817-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in colorectal cancers.
  • BACKGROUND: Although colorectal cancer is the most common cancer in Singapore, brain metastases associated with colorectal primaries are quite rare, with reported incidences ranging from less than 1% to 4%.
  • METHODS: From a prospectively collected database, 4378 patients underwent surgery for colorectal cancers between 1995 and 2003.
  • The median interval between surgery for the primary tumor and the discovery of a brain secondary was 27.5 months.
  • It may be recommended that a brain scan be performed to screen for a brain secondary when lung and/or liver metastases are discovered, especially in a patient with a left-sided cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Prognosis. Singapore / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1467-71 [10566536.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):541-5 [8620805.001]
  • [Cites] Dis Colon Rectum. 2007 Jan;50(1):102-14 [17115340.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2865-72 [15254054.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):807-17 [15108028.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1677-85 [10223560.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8512-9 [16260687.001]
  • [Cites] BMC Cancer. 2003 Oct 06;3:26 [14529575.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):711-6 [8756361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Apr 1;35(1):27-35 [8641923.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):1-5 [11036130.001]
  • [Cites] Surg Today. 1993;23(7):639-43 [8369617.001]
  • [Cites] J Surg Educ. 2007 Mar-Apr;64(2):114-9 [17462214.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10 ):779-86 [11776491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):797-802 [8138431.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):453-63 [8876887.001]
  • [Cites] Clin Colorectal Cancer. 2005 Jul;5(2):108-13 [16098251.001]
  • [Cites] J Nucl Med. 2008 Mar;49(3):480-508 [18287273.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1468-81 [17704239.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10 ):752-3 [11776485.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):551-7 [9028367.001]
  • (PMID = 19194739.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Evans MD, Escofet X, Karandikar SS, Stamatakis JD: Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol; 2009;7:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer.
  • BACKGROUND: The management of patients with surgically incurable bowel cancer at presentation is controversial.
  • It has been believed that the most effective palliation is achieved by resection of the primary cancer in order to pre-empt future complications.
  • This study reviews and compares the outcomes of patients with incurable bowel cancer managed by resection and non-resection strategies over a 7-year period in a single District General Hospital.
  • PATIENTS AND METHODS: All patients with surgically incurable bowel cancer at presentation were identified from the prospectively collected local ACPGBI database.
  • Survival, using Kaplan-Meier method and log-rank test, was compared between patients managed by resection of the primary, non-resectional intervention (surgery, stent & oncological treatments) and those managed with supportive care only.
  • The primary endpoint of the study was survival on an intention to treat basis, compared using Kaplan-Meier and log-rank tests.
  • RESULTS: Of 646 consecutive newly diagnosed bowel cancer patients over a 7 year period 154 cases (24%) were deemed surgically incurable at presentation.
  • Only one patient (2%) managed by non-resectional intervention required later surgery to treat primary tumour related complications.
  • CONCLUSION: In an unselected bowel cancer population surgical resection of the primary tumour in patients presenting with incurable disease does not improve survival and is associated with a high risk of post-operative mortality.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):636-52 [3042304.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):343-52 [7513600.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] Dis Colon Rectum. 1964 May-Jun;7:211-7 [14159372.001]
  • [Cites] Gut. 2005 Aug;54(8):1194-202 [16009693.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):465-74 [16523446.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):766-70 [17103261.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • (PMID = 19284542.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2657129
  •  go-up   go-down


33. Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Okuda J, Takeshita A, Shibayama Y, Tanigawa N: Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg; 2010;10:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis.
  • BACKGROUND: Hepatectomy is recommended as the most effective therapy for liver metastasis from colorectal cancer (CRCLM).
  • METHODS: Eighty-three patients undergoing initial hepatectomy for CRCLM were retrospectively analyzed with respect to characteristics of primary colorectal and metastatic hepatic tumors, operation details and prognosis.
  • Univariate analysis clarified that the significant prognostic factors for poor survival were depth of primary colorectal cancer (≥ serosal invasion), hepatic resection margin (< 5 mm), presence of portal vein invasion of CRCLM, and the presence of intra- and extrahepatic recurrence.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Hepatectomy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Mar;91(3):327-33 [14991634.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):256-63 [3827361.001]
  • [Cites] World J Surg. 1987 Aug;11(4):511-20 [3630196.001]
  • [Cites] Am J Surg. 1988 Mar;155(3):378-82 [3344897.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):332-7 [10201774.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(1):16-22 [10436233.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2038-48 [15774795.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):374-80 [15915371.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):295-300 [17667509.001]
  • [Cites] Br J Surg. 2007 Sep;94(9):1133-8 [17514637.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4575-80 [17925551.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):109-17 [18156930.001]
  • [Cites] Oncologist. 2008 Jan;13(1):51-64 [18245012.001]
  • [Cites] Surgery. 2008 Mar;143(3):384-93 [18291260.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Arch Surg. 2008 Aug;143(8):743-9; discussion 749-50 [18711033.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2472-81 [18594929.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Sep;7(8):778-831 [19755046.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):38-47 [19942479.001]
  • [Cites] Surgery. 2011 Mar;149(3):438-44 [20083286.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):653-7 [11066136.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):165-75 [11167863.001]
  • [Cites] Surgery. 2001 Apr;129(4):421-8 [11283532.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):887-94 [11521792.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1642-7 [11920523.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Jun;29(6):848-55 [12090034.001]
  • [Cites] Arch Surg. 2002 Jul;137(7):833-40 [12093342.001]
  • [Cites] J Pathol. 1986 Nov;150(3):195-203 [3806280.001]
  • (PMID = 20875094.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2949597
  •  go-up   go-down


34. Vishnevskiĭ VA, Efanov MG, Ikramov RZ, Shevchenko TV, Melekhina OV, Kozyrin IA: [Hilar glissonean access to vascular-secretory elements in anatomical segmental liver resections]. Khirurgiia (Mosk); 2008;(9):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hilar glissonean access to vascular-secretory elements in anatomical segmental liver resections].
  • It still remains unclear which patients with hepatic tumors can favour anatomical segmental liver resections instead of major liver resection.
  • Short term results of anatomical segmental liver resection are evaluated and analyzed.
  • Ten patients underwent the anatomical segmental liver resection performed by posterior approach with taping of anterior right hepatic vein.
  • Seven patients had liver metastases of colorectal cancer, one had primary hepatic carcinoma and two had benign lesions, anatomical segmental liver resection were performed without Pringle maneuver.
  • There was no significant difference in blood loss, duration of the procedure, postoperative hospital stay and morbidity in comparison with the segmental liver resection performed by anterior approach.
  • Anatomical segmental liver resection performed by hilar glissonean approach is recommended in patients with compromised liver function "unfavourable" liver anatomy to replace major liver resection provides removal of only affected part of the liver accordingly to its true anatomical borders.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical / prevention & control. Follow-Up Studies. Humans. Length of Stay. Magnetic Resonance Imaging. Middle Aged. Retrospective Studies. Severity of Illness Index. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833181.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


35. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, Wilhelm K, Biersack HJ, Ezziddin S: The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med; 2010 Aug;51(8):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.
  • Selective internal radiation therapy (SIRT), a catheter-based liver-directed modality for treating primary and metastatic liver cancer, requires appropriate planning to maximize its therapeutic response and minimize its side effects. (99m)Tc-macroaggregated albumin (MAA) scanning should precede the therapy to detect any extrahepatic shunting to the lung or gastrointestinal tract.
  • METHODS: Ninety diagnostic hepatic angiograms with (99m)Tc-MAA were obtained for 76 patients with different types of cancer.
  • [MeSH-major] Liver / radionuclide imaging. Liver Circulation / physiology. Liver Neoplasms / drug therapy. Liver Neoplasms / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Aggregated Albumin. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Abdomen / radionuclide imaging. Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Embolization, Therapeutic. Female. Gallbladder / metabolism. Gallbladder / radionuclide imaging. Humans. Image Interpretation, Computer-Assisted. Male. Microspheres. Middle Aged. Patient Care Planning. Radionuclide Angiography. Reference Standards. Tomography, Emission-Computed. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660379.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / Yttrium Radioisotopes
  •  go-up   go-down


36. Metcalfe MS, Mullin EJ, Maddern GJ: Hepatectomy for metastatic noncolorectal gastrointestinal, breast and testicular tumours. ANZ J Surg; 2006 Apr;76(4):246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For other primary diseases, however, the overall number of cases is relatively small, and it is more difficult to derive clear guidelines.
  • This paper reviews the reported experience of hepatectomy for metastases from non-colorectal gastrointestinal primary cancers, breast cancer and testicular teratoma.
  • The data collected included the primary disease, the number of cases reported, the survival post-hepatectomy and any prognostic factors associated with outcome.
  • [MeSH-major] Breast Neoplasms / pathology. Gastrointestinal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Gastrointestinal Stromal Tumors / secondary. Gastrointestinal Stromal Tumors / surgery. Humans. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Male. Sarcoma / secondary. Sarcoma / surgery. Stomach Neoplasms / pathology. Teratoma / secondary. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681543.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 54
  •  go-up   go-down


37. Zhang HZ, Dong SX, Zhou ZX, Shao YF: [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases]. Zhonghua Yi Xue Za Zhi; 2007 Jun 5;87(21):1457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of surgical therapy for liver metastasis of colorectal cancer: analysis of 75 cases].
  • OBJECTIVE: To explore the strategy to improve the long term survival of liver metastasis of colorectal cancer after surgical treatment.
  • METHODS: The clinical data of 75 patients with liver metastasis of colorectal cancer, 43 males and 32 females, aged 51.4, who received hepatectomy between January 1981 and November 2005, were analyzed.
  • RESULTS: The primary tumor site was colon in 39 cases, and rectum in 36 cases.
  • Liver metastasis was synchronous in 59 patients, and metachronous in 16 patients.
  • 45 patients received simultaneous liver and colorectal resection, 29 patients received metachronous resection, and 1 patient did not receive primary rectal cancer resection.
  • CONCLUSION: Surgical resection of liver metastasis of colorectal cancer significantly prolongs the survival time, and resection of all liver deposits and the extrahepatic disease is the most important factor influencing survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome


38. Watanabe T, Kobunai T, Yamamoto Y, Kanazawa T, Konishi T, Tanaka T, Matsuda K, Ishihara S, Nozawa K, Eshima K, Muto T, Nagawa H: Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer; 2010 Jul;46(11):2119-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes.
  • PURPOSE: Liver metastasis is one of the major types of recurrence after surgery for colorectal cancer.
  • Traditional methods of predicting liver metastasis are limited in their accuracy, suggesting the need to develop new predictors.
  • We developed a 10-gene signature that is closely associated with the development of liver metastasis after colorectal cancer.
  • PATIENTS AND METHODS: We examined a total of 189 frozen specimens of primary colorectal cancers using both microarray and quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis.
  • Initially, we studied gene expression in colorectal cancer tissue from 160 randomly selected patients who had undergone surgical resection of colorectal cancer and evaluated the association between the level of gene expression and the occurrence of liver metastasis.
  • We developed a gene-expression model for the prediction of liver metastasis based on the RT-PCR findings.
  • RESULTS: The expression of 14 genes was correlated with liver metastasis according to both microarray and RT-PCR analysis.
  • The 10-gene signature was an independent predictor of liver metastasis.
  • CONCLUSION: The 10-gene signature identified in this study is closely associated with the occurrence of liver metastasis in colorectal cancer patients.
  • [MeSH-major] Colorectal Neoplasms / genetics. Genes, Neoplasm / genetics. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression. Humans. Male. Microarray Analysis. Middle Aged. Predictive Value of Tests. Reverse Transcriptase Polymerase Chain Reaction. Young Adult


39. Tischoff I, Tannapfel A: [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy]. Zentralbl Chir; 2007 Aug;132(4):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary liver cancer is one of the most common cancer worldwide.
  • Beside hepatocellular carcinoma (HCC), accounting for more than 80%, cholangiocarcinoma (CC) is the second most frequent primary malignant epithelial liver tumor.
  • Combined hepatocellular-cholangiocarcinoma (HCC/CC) is a rare form of liver cancer with a frequency of 1%.
  • The UICC-TNM classification of malignant liver tumors is applied for both tumor entities.
  • 70-80% of hepatocellular carcinoma occur in cirrhotic liver.
  • In high incidence areas, such as Asia and Africa, HCC is strongly associated with chronic viral hepatitis B and C and liver cirrhosis.
  • But several risk factors including hepatolithiasis, liver fluke infection, and anatomical abnormalities associated with inflammation of the biliary tract have been described.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Liver Neoplasms
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidence. Liver / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724632.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


40. Garg K, Soslow RA, Rivera M, Tuttle MR, Ghossein RA: Histologically bland "extremely well differentiated" thyroid carcinomas arising in struma ovarii can recur and metastasize. Int J Gynecol Pathol; 2009 May;28(3):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients presented with disseminated PTC 3 and 4 years after the initial diagnosis, involving the pelvis in both cases and also the liver parenchyma in 1 case.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Struma Ovarii / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Iodine Isotopes / therapeutic use. Middle Aged. Ovariectomy. Pregnancy. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620939.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Isotopes
  •  go-up   go-down


41. Dalenc F, Doisneau-Sixou SF, Allal BC, Marsili S, Lauwers-Cances V, Chaoui K, Schiltz O, Monsarrat B, Filleron T, Renée N, Malissein E, Meunier E, Favre G, Roché H: Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin Cancer Res; 2010 Feb 15;16(4):1264-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
  • PURPOSE: Tipifarnib, a farnesyltransferase inhibitor, has antitumor activity in heavily pretreated metastatic breast cancer patients.
  • EXPERIMENTAL DESIGN: Postmenopausal patients with measurable estrogen receptor- and/or progesterone receptor-expressing metastatic breast cancers were enrolled.
  • RESULTS: Twenty patients were enrolled and evaluated for efficacy: one patient had an objective response (liver metastasis) and nine had stable disease after 6 months for a clinical benefit rate of 50%; median duration of benefit was 10.3 (range, 7.4-20.2) months.
  • CONCLUSIONS: Because the primary end point of efficacy (three objective responses) was not achieved, the study is negative.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Farnesyltranstransferase / administration & dosage. Female. Humans. Middle Aged. Neoplasm Metastasis. Postmenopause. Protein Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145184.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinolones; 094ZI81Y45 / Tamoxifen; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


42. Sun Y, Shang G, Bao YX, Zhang H: [Prognostic analysis of 77 cases of rectal cancer with synchronous liver metastases]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):622-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 77 cases of rectal cancer with synchronous liver metastases].
  • OBJECTIVE: To explore the prognostic factors for rectal cancer patients with synchronous liver metastases.
  • METHODS: Data from a total of 77 cases of rectal cancer with synchronous liver metastases treated in our center from January 2002 to December 2008 were collected and reviewed.
  • Univariate analysis with Kaplan-Meier method revealed that the differentiation of the primary tumor, T-stage, N status, the distribution, number and size of liver metastases, extrahepatic disease, serum CEA level at diagnosis and treatment modality were prognostic factors (P < 0.05).
  • Multivariate analysis showed that the differentiation of the primary tumor (P = 0.007), T-stage (P = 0.027), the size of liver metastases (P = 0.003), serum CEA value at diagnosis (P = 0.000) were independent prognostic factors for rectal cancer patients with synchronous liver metastases.
  • CONCLUSION: The factors affecting the prognosis for rectal cancer patients with synchronous liver metastases are the differentiation of the primary tumor, T-stage, N status, the distribution, number and size of liver metastases, extrahepatic disease, serum CEA level at diagnosis and treatment modality.
  • The differentiation of the primary tumor, T-stage, the size of liver metastases, and serum CEA value at diagnosis are independent prognostic factors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122418.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


43. He YF, Li YH, Zhang DS, Xiang XJ, Xu RH, Pan ZZ, Zhou ZW, Jiang WQ, He YJ, Wan DS: [Prognostic analysis of 220 colorectal cancer patients with synchronous liver metastases]. Ai Zheng; 2006 Sep;25(9):1153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 220 colorectal cancer patients with synchronous liver metastases].
  • BACKGROUND & OBJECTIVE: Colorectal cancer is one of the most common malignant tumors in China.
  • Synchronous liver metastases occur in 10%-25% colorectal cancer patients.
  • This study was to elucidate the prognostic factors and treatment choices for colorectal cancer patients with synchronous liver metastases.
  • METHODS: Records of 220 colorectal cancer patients with synchronous liver metastases initially treated at Cancer Center of Sun Yat-sen University from Dec.
  • Univariate analysis of clinical characteristics revealed that the number, size and distribution of liver metastases, extrahepatic disease, serum CEA level at diagnosis, N status, and histology were prognostic factors.
  • Univariate analysis of clinical treatment factors showed that treatment modality, primary site resection, and chemotherapy regimen were prognostic factors.
  • Multivariate analysis showed that the number and size of liver metastases, extrahepatic disease, serum CEA value at diagnosis, treatment modality, primary tumor resection, and chemotherapy regimen were independent prognostic factors of colorectal cancer patients with synchronous liver metastases.
  • CONCLUSIONS: Liver metastases larger than 5 cm in diameter, bilobar liver metastases, extrahepatic invasion or metastases, and CEA level more than 200 microg/L at diagnosis are adverse prognostic factors.
  • Primary tumor resection and liver resection should be considered for all suitable patients with colorectal metastases to the liver alone.
  • Liver-target intervention and/or systemic chemotherapy might be a good choice for inoperable patients.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Combined Modality Therapy. Female. Follow-Up Studies. Hepatectomy. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Survival Rate


44. Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F: Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg; 2005 Feb;9(2):178-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine prognostic factors and outcome after liver resection for colorectal metastases in 102 patients over a period of 10 years.
  • Of 19 patients with isolated liver recurrence, 6 had a second metastasectomy; 4 of the 6 are still alive.
  • We found that the number of hepatic lesions on computed tomography (P=0.012), the interval between resection of the primary colon tumor and the hepatic metastasectomy (P=0.012), and synchronicity of the primary and the hepatic metastasis (P=0.048) showed evidence of independent prognostic value regarding survival.
  • Patients with recurrence after a first liver resection may benefit from a repeat metastasectomy.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Radiology. 1996 Dec;201(3):798-802 [8939234.001]
  • [Cites] Surgery. 1986 Aug;100(2):278-84 [3526605.001]
  • [Cites] Cancer. 1969 Jan;23(1):198-202 [5763253.001]
  • [Cites] Surg Clin North Am. 1989 Apr;69(2):339-59 [2928902.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):337-52 [9019355.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):275-81 [10587183.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] Surg Clin North Am. 1993 Feb;73(1):145-66 [8426994.001]
  • [Cites] Eur J Surg Oncol. 1998 Jun;24(3):174-9 [9630855.001]
  • [Cites] Ann Surg. 1994 Jan;219(1):13-7 [8297171.001]
  • [Cites] Bull Cancer. 1998 Nov;85(11):935-50 [9951421.001]
  • [Cites] Surg Oncol Clin N Am. 1996 Apr;5(2):353-64 [9019356.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(1):30-8 [10436235.001]
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):47-53 [11192922.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2321-8 [10521990.001]
  • [Cites] Surg Gynecol Obstet. 1968 Jul;127(1):1-11 [5657778.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):685-93 [2961314.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Cancer. 1993 Jun 15;71(12 Suppl):4252-66 [8508388.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • (PMID = 15694813.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Huh JW, Cho CK, Kim HR, Kim YJ: Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases. J Gastrointest Surg; 2010 Aug;14(8):1258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases.
  • PURPOSE: This study was designed to evaluate the impact of resection for primary colorectal cancer on oncologic outcomes in patients with synchronous colorectal liver metastases.
  • METHODS: A retrospective analysis was performed on 91 consecutive patients with synchronous colorectal liver metastases who underwent resection of the primary colorectal cancer between December 1999 and December 2007.
  • Of the 91 patients, 54 (59.3%) also underwent complete (R0) resection for liver metastases, and 84 (92.3%) received postoperative chemotherapy.
  • A multivariate analysis revealed that residual disease after surgery (non-R0 resection; p = 0.003), lymph node metastasis of the primary tumor (p = 0.015), and no postoperative chemotherapy (p = 0.001) were independent prognostic factors for poor survival.
  • Independent predictors of an inability to achieve a complete resection were the presence of three or more liver metastases and the presence of extrahepatic disease at exploration.
  • CONCLUSIONS: The inability to safely render the liver and colon microscopically free of disease should cause a surgeon to reconsider synchronous colectomy and hepatectomy.
  • A multidisciplinary approach that combines both complete resection of synchronous colorectal liver metastases and postoperative chemotherapy may achieve improved survival in patients with synchronous colorectal liver metastases.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Hepatectomy / methods. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Portography. Positron-Emission Tomography. Republic of Korea / epidemiology. Retrospective Studies. Survival Rate / trends. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):786-94 [17103254.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Ann Surg Oncol. 2009 Feb;16(2):361-70 [19050976.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):125-35 [18156932.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):274-80 [14993022.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1776-82 [17710496.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1081-4 [9278645.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1210-4 [15277260.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2038-48 [15774795.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S115-22 [8313782.001]
  • [Cites] Br J Surg. 1995 May;82(5):669-71 [7613949.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • (PMID = 20544397.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Pothiwala P, Jain SK, Yaturu S: Metabolic syndrome and cancer. Metab Syndr Relat Disord; 2009 Aug;7(4):279-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome and cancer.
  • Since its first description by Reavan in 1988, accepted criteria for clinical identification of the components of metabolic syndrome have been promulgated by the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) and the World Health Organization (WHO) as well as the International Diabetes Federation (IDF), and the American Association of Clinical Endocrinologists (AACE).
  • Although ATP III identified cardiovascular disease (CVD) as the primary clinical outcome of the metabolic syndrome, we now have evidence that metabolic syndrome is associated with type 2 diabetes mellitus, polycystic ovarian disease, nonalcoholic fatty liver disease, and possibly some cancers.
  • This review summarizes evidence in support of the relationship between metabolic syndrome and various cancers and possible underlying mechanisms and therapeutic interventions.
  • [MeSH-minor] Adult. Cardiovascular Diseases / complications. Cardiovascular Diseases / diagnosis. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / diagnosis. Disease Progression. Endocrinology / methods. Female. Humans. Insulin Resistance. Male. Middle Aged. Models, Biological. PPAR gamma / metabolism. Risk Factors

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):287-93 [12020111.001]
  • [Cites] JAMA. 2002 Dec 4;288(21):2709-16 [12460094.001]
  • [Cites] Circulation. 2002 Dec 17;106(25):3143-421 [12485966.001]
  • [Cites] Eur J Cancer Prev. 2003 Aug;12(4):309-15 [12883384.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1237-42 [14520453.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]
  • [Cites] Endocrinology. 2008 Dec;149(12):6272-9 [18703630.001]
  • [Cites] Lancet. 2005 Sep 24-30;366(9491):1059-62 [16182882.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(4):316-20 [16158078.001]
  • [Cites] Gut. 2006 Jan;55(1):62-7 [15972299.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4258-65 [11095464.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):13-21 [11227921.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7 [11469677.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1044-50 [15480982.001]
  • [Cites] Diabetes. 1988 Dec;37(12):1595-607 [3056758.001]
  • [Cites] Am J Epidemiol. 1990 Feb;131(2):254-62 [2296978.001]
  • [Cites] Cancer Causes Control. 1994 Nov;5(6):501-9 [7827236.001]
  • [Cites] Epidemiology. 1995 Mar;6(2):137-41 [7742399.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):26746-9 [7592907.001]
  • [Cites] N Engl J Med. 1996 Apr 11;334(15):952-7 [8596596.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Circulation. 1998 Aug 4;98(5):398-404 [9714089.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1418-21 [18027857.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s823-35 [18265476.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s836-42 [18265477.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] Oncol Rep. 2008 Mar;19(3):787-93 [18288417.001]
  • [Cites] Am J Epidemiol. 2008 Jul 1;168(1):49-57 [18448441.001]
  • [Cites] Int J Cancer. 2008 Oct 15;123(8):1877-82 [18651569.001]
  • [Cites] Diabetologia. 2008 Oct;51(10):1757-60 [18696045.001]
  • [Cites] Lung Cancer. 2008 Sep;61(3):292-300 [18342390.001]
  • [Cites] Endocr Pract. 2003 Sep-Oct;9 Suppl 2:23-5 [14698969.001]
  • [Cites] Int J Epidemiol. 2004 Feb;33(1):217-25 [15075172.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):267-75 [15090721.001]
  • [Cites] Diabetologia. 2004 Jun;47(6):1071-8 [15164171.001]
  • [Cites] Growth Horm IGF Res. 2004 Aug;14(4):261-9 [15231294.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):542-7 [10088625.001]
  • [Cites] Pharmacol Rev. 2004 Dec;56(4):549-80 [15602010.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):194-202 [15644546.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):133-7 [15668486.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1304-5 [15849206.001]
  • [Cites] Am J Epidemiol. 2005 Jun 15;161(12):1107-14 [15937019.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jun;3(6):587-94 [15952101.001]
  • [Cites] Urology. 2005 Jun;65(6):1168-72 [15922427.001]
  • [Cites] Clin Res Cardiol. 2008 Apr;97(4):227-33 [18060375.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2437-45 [18338750.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):921-9 [18398032.001]
  • [Cites] Dis Colon Rectum. 2008 May;51(5):593-7 [18219529.001]
  • [Cites] Arch Physiol Biochem. 2008 Feb;114(1):84-98 [18465362.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):450-6 [18449887.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 24;340(4):1158-66 [16403434.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Oct-Dec;6(4):485-9 [16435997.001]
  • [Cites] Diabetes Care. 2006 Feb;29(2):254-8 [16443869.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1830-7 [16410309.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8 [16434464.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):236-8 [16450399.001]
  • [Cites] Diabetologia. 2006 May;49(5):945-52 [16557372.001]
  • [Cites] Diabet Med. 2006 May;23(5):469-80 [16681555.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):659-67 [16572422.001]
  • [Cites] Int J Hematol. 2006 Apr;83(3):254-8 [16720558.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):920-31 [16818856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1331-5 [16835332.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):989-1003 [16933050.001]
  • [Cites] Am J Epidemiol. 2006 Oct 1;164(7):652-64 [16877536.001]
  • [Cites] Obes Rev. 2006 Nov;7(4):333-40 [17038127.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1505-22 [17071576.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1647-54 [17105987.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2391-7 [17164361.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9 [17179486.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1573-8 [17205522.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Feb;5(2):221-9; quiz 141 [16931168.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):535-9 [17109938.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Dec;25(4):537-41 [17310845.001]
  • [Cites] Diabetes Care. 2007 Mar;30(3):561-7 [17327321.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1993-8 [17266034.001]
  • [Cites] Breast Cancer Res. 2007;9(1):201 [17224037.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1457-61 [17375043.001]
  • [Cites] J Cell Physiol. 2007 Jul;212(1):1-12 [17443682.001]
  • [Cites] Mini Rev Med Chem. 2007 Jun;7(6):599-608 [17584158.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1564-70 [17443495.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1543-6 [17684126.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):753-61 [17715409.001]
  • [Cites] Obes Rev. 2007 Sep;8(5):395-408 [17716297.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):556-65 [17823417.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2512-6 [17680557.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):1005-8 [17700568.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):713-20 [17914101.001]
  • [Cites] Gastroenterology. 2007 Nov;133(5):1423-9 [17904132.001]
  • [Cites] Ann Clin Lab Sci. 2007 Autumn;37(4):343-8 [18000291.001]
  • [Cites] BMJ. 2007 Dec 1;335(7630):1134 [17986716.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):293-7 [18055193.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Anticancer Drugs. 2002 Feb;13(2):127-37 [11901304.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):385-91 [11927499.001]
  • (PMID = 19284314.001).
  • [ISSN] 1557-8518
  • [Journal-full-title] Metabolic syndrome and related disorders
  • [ISO-abbreviation] Metab Syndr Relat Disord
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK072433
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PPAR gamma
  • [Number-of-references] 99
  • [Other-IDs] NLM/ PMC3191378
  •  go-up   go-down


47. Kusumi E, Kami M, Kanda Y, Murashige N, Seki K, Fujiwara M, Koyama R, Komatsu T, Hori A, Tanaka Y, Yuji K, Matsumura T, Masuoka K, Wake A, Miyakoshi S, Taniguchi S: Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. Biol Blood Marrow Transplant; 2006 Dec;12(12):1302-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
  • Liver injury is a common complication in allogeneic hematopoietic stem cell transplantation.
  • Its major causes comprise graft-versus-host disease (GVHD), infection, and toxicities of preparative regimens and immunosuppressants; however, we have little information on liver injuries after reduced intensity cord blood transplantation (RICBT).
  • We assessed the etiology of liver injuries based on the clinical presentation, laboratory results, comorbid events, and imaging studies in 85 patients who achieved primary engraftment.
  • The severity of liver dysfunction was assessed according to the National Cancer Institute Common Toxicity Criteria version 2.0.
  • Moderate to very severe liver injuries were observed in 36 patients.
  • Their causes included cholestatic liver disease (CLD) related to GVHD or sepsis (n = 15), GVHD (n = 7), cholangitis lenta (n = 5), and others (n = 9).
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Hematologic Diseases / surgery. Liver Diseases / epidemiology. Postoperative Complications / epidemiology. Transplantation Conditioning / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents / adverse effects. Anti-Bacterial Agents / therapeutic use. Bacterial Infections / epidemiology. Busulfan / administration & dosage. Busulfan / adverse effects. Cholangitis / epidemiology. Cholangitis / etiology. Cyclosporine / adverse effects. Cyclosporine / therapeutic use. Drug-Induced Liver Injury / epidemiology. Drug-Induced Liver Injury / etiology. Female. Hematologic Neoplasms / complications. Hematologic Neoplasms / surgery. Hepatic Veno-Occlusive Disease / epidemiology. Hepatic Veno-Occlusive Disease / etiology. Humans. Hyperbilirubinemia / epidemiology. Hyperbilirubinemia / etiology. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Incidence. Infant, Newborn. Liver Function Tests. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Risk Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use. Tissue Donors. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives. Whole-Body Irradiation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162212.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


48. Gomyo H, Kagami Y, Kato H, Kawase T, Ohshiro A, Oyama T, Kamiya Y, Taji H, Nakamura S, Ogura M, Morishima Y: Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. J Clin Exp Hematop; 2007 Nov;47(2):73-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes.
  • This report concerns a rare case of follicular lymphoma with features suggestive of primary hepatic lymphoma.
  • At the disease onset, multiple nodular lesions in the liver and small para-aortic nodes were detected by abdominal magnetic resonance imaging without generalized lymphadenopathy.
  • To the best of our knowledge, this is the ninth report of primary hepatic follicular lymphoma.
  • Insufficient cases have been reported to determine the long-term outcome and clinical characteristics of primary hepatic follicular lymphoma.
  • However, it seems that patients with primary hepatic follicular lymphoma that are treated with appropriate chemotherapy with or without surgical resection have favorable outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cholecystitis / pathology. Cyclophosphamide. Doxorubicin. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Prednisone. Remission Induction. Rituximab. Vincristine

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040146.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


49. Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP: Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther; 2008 Aug;7(8):2498-508
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to expand these experiments to human colorectal cancer.
  • Tissue samples of normal colon, benign adenomas, colorectal carcinomas, and liver metastases from 111 patients were obtained for the quantification of the expression of the cellular STxB receptor, the glycosphingolipid globotriaosyl ceramide (Gb(3) or CD77).
  • Short-term primary cultures were prepared from samples of 43 patients, and STxB uptake was studied by immunofluorescence microscopy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromatography, Thin Layer. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Trihexosylceramides / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18687997.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Gb3 antigen; 0 / Shiga Toxins; 0 / Trihexosylceramides; 0 / stxB toxin; 71965-57-6 / globotriaosylceramide
  •  go-up   go-down


50. Shimizu T, Arima Y, Yokomuro S, Yoshida H, Mamada Y, Nomura T, Taniai N, Aimoto T, Nakamura Y, Mizuguchi Y, Kawahigashi Y, Uchida E, Akimaru K, Tajiri T: Incidental gallbladder cancer diagnosed during and after laparoscopic cholecystectomy. J Nippon Med Sch; 2006 Jun;73(3):136-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental gallbladder cancer diagnosed during and after laparoscopic cholecystectomy.
  • One patient with a pT2 tumor with metastases to the liver and pericholedochal lymph nodes found with additional resection died of recurrence of metastasis to the liver and lung 70 months after LC.
  • One patient with a pT2 tumor died of primary lung cancer 35 months after LC.
  • Patients with T1b tumors should undergo liver-bed resection and lymphadenectomy, and patients with >pT2 tumors should undergo systematic liver resection with lymphadenectomy.
  • [MeSH-minor] Adult. Aged. Biliary Tract Surgical Procedures. Female. Hepatectomy. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790980.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Conrad R, Remberger M, Cederlund K, Ringdén O, Barkholt L: A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Haematologica; 2008 Feb;93(2):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND METHODS: Allogeneic stem cell transplantation was performed in 48 patients with metastatic renal cell cancer (n=17), colo-rectal cancer (n=15), non-metastatic advanced primary liver cancer after orthotopic liver transplantation (n=11), and other solid tumors (n=5).
  • The best graft-versus-tumor effect was demonstrated in patients with advanced primary liver cancer who had previously undergone liver transplantation (p=0.018).
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / immunology. Disease-Free Survival. Female. Graft Survival. Graft vs Host Disease / immunology. Graft vs Host Disease / mortality. Graft vs Host Disease / therapy. Humans. Male. Middle Aged. Survival Rate. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245651.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Sperti E, Faggiuolo R, Gerbino A, Magnino A, Muratore A, Ortega C, Ferraris R, Leone F, Capussotti L, Aglietta M: Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach. Dis Colon Rectum; 2006 Oct;49(10):1596-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach.
  • PURPOSE: New chemotherapy agents and integrated treatments have improved the prognosis of patients with metastatic colorectal cancer.
  • They were divided initially into four treatment groups: A, palliative chemotherapy for extensive extrahepatic disease with or without hepatic disease (97 patients); B, palliative chemotherapy as in Group A for extensive hepatic disease unlikely to become resectable (36 patients); C, neoadjuvant chemotherapy for potentially resectable liver metastases if responsive to therapy (33 patients); D, immediate surgery for liver metastases (63 patients).
  • The outcome was considered for the 69 patients with metastases confined to the liver (Groups B and C), who were treated initially with chemotherapy.
  • However, patients resected after chemotherapy obtained overall survival similar to that of primary surgery, suggesting a positive role for integrated approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neoadjuvant Therapy. Outcome Assessment (Health Care). Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Middle Aged. Organoplatinum Compounds / therapeutic use. Survival Analysis. Treatment Outcome


53. Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE: Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug Metab Dispos; 2007 Oct;35(10):1963-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases.
  • The present study was conducted to investigate the expression of hepatobiliary efflux transporters in livers from patients after toxic acetaminophen (APAP) ingestion, with livers from patients with primary biliary cirrhosis (PBC) serving as positive controls. mRNA and protein expression of multidrug resistance-associated protein (MRP) 1-6, multidrug resistance protein (MDR) 1-3/P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) in normal (n = 6), APAP overdose (n = 5), and PBC (n = 6) human liver samples were determined by branched DNA and Western blot analysis, respectively.
  • Compared with normal liver specimens, MRP1 and MRP4 mRNA levels were elevated after APAP overdose and in PBC.
  • The findings from this study demonstrate that hepatic efflux transporter expression is up-regulated in cases of APAP-induced liver failure and PBC.
  • The close proximity of P-gp and PCNA-positive hepatocytes during liver injury suggests that along with cell regeneration, increased efflux transporter expression is a critical response to hepatic damage to protect the liver from additional insult.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Acetaminophen / poisoning. Analgesics, Non-Narcotic / poisoning. Liver / metabolism. Liver Cirrhosis, Biliary / metabolism. Liver Failure, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Drug Overdose. Humans. Middle Aged. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 981477898 for PMID:17627974 [PharmGKB] .
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627974.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068039; United States / NIDDK NIH HHS / DK / DK068039; United States / NIDDK NIH HHS / DK / DK069557; United States / NIDDK NIH HHS / DK / N01-DK-9-2310
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / Analgesics, Non-Narcotic; 0 / RNA, Messenger; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


54. Zhang ZY, Zhao ZR, Adell G, Jarlsfelt I, Cui YX, Kayed H, Kleeff J, Wang MW, Sun XF: Expression of MAC30 in rectal cancers with or without preoperative radiotherapy. Oncology; 2006;71(3-4):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MAC30 in rectal cancers with or without preoperative radiotherapy.
  • OBJECTIVE: Meningioma-associated protein (MAC30) is overexpressed in several types of cancers, but its therapeutic implication in the patients has not been studied.
  • We examined the relationship of MAC30 with clinicopathological and biological factors in rectal cancer patients with or without radiotherapy (RT).
  • METHODS: MAC30 was immunohistochemically examined in 75 distant and 91 adjacent normal mucosa specimens, 132 primary tumours and 39 lymph node metastases from rectal cancer patients participating in a clinical trial of preoperative RT.
  • RESULTS: In the RT group, MAC30 was or tended to be positively correlated with infiltrated growth pattern (p = 0.02), PRL (phosphatase of regenerating liver, p = 0.01) and Ki-67 expression (p = 0.06).
  • MAC30 in primary tumours was not related to recurrence and survival in the non-RT or RT group.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657172.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / TMEM97 protein, human
  •  go-up   go-down


55. Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO: The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol); 2008 Feb;20(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of basal phenotype on the metastatic pattern of breast cancer.
  • AIMS: To assess whether basal phenotype influences the metastatic pattern and survival in patients with metastatic breast cancer.
  • MATERIALS AND METHODS: The basal phenotype status of a well-characterised series of consecutive primary operable breast cancers (1868 cases) was ascertained using the basal cytokeratin markers CK5/6 and CK14.
  • Follow-up data, including time, site and pattern of distant metastasis and post-metastasis survival, were available for 113 women with basal phenotype cancers and they were compared with 178 matching cases from women in the non-basal phenotype group.
  • There was no significant difference in the frequency of pleural or liver metastases between both groups.
  • The multivariate analysis, including other established prognostic variables in breast cancer, showed that basal phenotype is an independent poor prognostic factor.
  • CONCLUSION: Intrapulmonary and brain metastases are seen more frequently at metastatic presentation in basal phenotype breast cancer patients, and the basal phenotype is associated with a poorer survival after metastatic presentation.
  • Assessment of basal cytokeratin expression status may provide valuable prognostic information relevant to breast cancer patients' management.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Female. Humans. Keratin-14 / analysis. Keratin-5 / analysis. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981444.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-14; 0 / Keratin-5
  •  go-up   go-down


56. Bergman L, Nilsson B, Ragnarsson-Olding B, Seregard S: Uveal melanoma: a study on incidence of additional cancers in the Swedish population. Invest Ophthalmol Vis Sci; 2006 Jan;47(1):72-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uveal melanoma: a study on incidence of additional cancers in the Swedish population.
  • PURPOSE: To investigate the occurrence of other primary malignancies before and after diagnosis of uveal melanoma in a Swedish population.
  • METHODS: In the Swedish Cancer Registry 2995 patients with uveal melanoma were notified during the period 1960 to 1998.
  • RESULTS: Before the diagnosis of uveal melanoma, the odds ratio (OR) for the risk of cancer was 1.25 (95% CI: 0.98-1.59).
  • The risk of subsequent cancers was increased, SIR 1.13 (95% CI: 1.02-1.26).
  • CONCLUSIONS: An increased risk of second primary cancers was observed among Swedish patients with uveal melanoma.
  • Metastases from uveal melanoma were found to be misclassified as cutaneous melanoma or as primary liver cancer.
  • [MeSH-major] Melanoma / epidemiology. Neoplasms, Second Primary / epidemiology. Uveal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Comorbidity. Female. Humans. Incidence. Male. Middle Aged. Odds Ratio. Registries. Risk Factors. Sweden / epidemiology

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16384946.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Capussotti L, Vigano' L, Ferrero A, Lo Tesoriere R, Ribero D, Polastri R: Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol; 2007 Mar;14(3):1143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model.
  • BACKGROUND: Timing of hepatectomy for synchronous metastases of colorectal cancer is still debated.
  • The aim of this retrospective study was to analyze prognostic factors after synchronous and delayed liver resections to define selection criteria for choosing timing of hepatectomy.
  • Patients with more than three metastases had a significantly worse survival in group A than in group B (3-year survival, 15.0% vs. 34.3%, P = .007); similarly, borderline significant difference was encountered in patients with T4 primary tumor (3-year survival, 16.7% vs. 60%, P = .064) CONCLUSIONS: Patients with liver metastases synchronous with colorectal cancer with T4 primary tumor, metastasis infiltration of neighboring structures, and especially with more than three metastases should receive neoadjuvant chemotherapy before liver resection.
  • [MeSH-major] Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Patient Selection. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Sep;14(9):2435-6 [17562115.001]
  • (PMID = 17200913.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P, Le Guludec D: Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer; 2009 Sep;16(3):977-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
  • Liver metastases are common in gastroenteropancreatic neuroendocrine tumors and significantly impair survival.
  • The records of 41 consecutive patients undergoing exhaustive resection of liver-only endocrine metastases and followed between 1992 and 2006 were reviewed.
  • All identified primary had been resected.
  • MI studies including abdominal computed tomography (CT) and/or liver magnetic resonance imaging and thoracic CT if indicated were performed every 6 months; SRS timing was decided by referring clinician.
  • Recurrences developed in 32 patients (78%), mainly in the liver (n=24) after a median of 19 months (2-79).
  • In conclusion, despite exhaustive liver surgery for endocrine metastases, hepatic or extra-hepatic recurrences are frequent and develop early.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / secondary. Neuroendocrine Tumors / surgery
  • [MeSH-minor] Adult. Aged. Diagnostic Imaging / methods. Female. Follow-Up Studies. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / mortality. Gastrointestinal Neoplasms / pathology. Hepatectomy / methods. Humans. Male. Middle Aged. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology. Postoperative Period. Predictive Value of Tests. Prognosis. Receptors, Somatostatin / metabolism. Retrospective Studies. Tomography, Emission-Computed / methods. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470616.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Somatostatin
  •  go-up   go-down


59. Tawada K, Ishihara T, Kobayashi A, Yamaguchi T, Tsuyuguchi T, Matsuyama M, Yokosuka O: Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis. Clin Cancer Res; 2008 Nov 15;14(22):7438-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
  • PURPOSE: In pancreatic carcinoma, vascular endothelial growth factor (VEGF) expression at the primary site has been suggested to be a prognostic parameter.
  • We quantitatively analyzed VEGF expression in liver metastases from pancreatic carcinoma and examined the correlation among VEGF expression in liver metastases, clinicopathologic factors, and clinical outcome.
  • EXPERIMENTAL DESIGN: The subjects consisted of 23 patients with pancreatic adenocarcinoma who had liver metastases and were treated with S-1 and gemcitabine as the first-line treatment.
  • VEGF expression was quantitated by enzyme immunoassay in biopsy specimens of liver metastases and nontumorous liver tissue, and in plasma.
  • In 10 of the 23 patients, VEGF expression was also quantitated in biopsy specimens of the primary pancreatic tumor.
  • RESULTS: The VEGF level in nontumorous liver tissue was 36.6 +/- 10.0 pg/mg protein versus 376.8 +/- 106.1 pg/mg protein in liver metastases (P = 0.0016).
  • Pretreatment VEGF levels in plasma and in primary pancreatic carcinoma did not correlate with VEGF levels in the corresponding liver metastases.
  • The median VEGF level in liver metastases (138.9 pg/mg protein) was used as the cutoff value between high and low VEGF expression in liver metastases.
  • Patients showing high VEGF expression had a significantly longer progression-free survival and overall survival than patients showing low VEGF expression in liver metastases (P = 0.0219 and P = 0.0074, respectively).
  • CONCLUSIONS: Evaluation of VEGF levels in liver metastases might be useful in assessing the prognosis of patients with metastatic pancreatic carcinoma who are under systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Liver Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18974391.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Vascular Endothelial Growth Factor A; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


60. Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabé R, Vicente D, Jiménez J, Lopez-Ladrón A: Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol; 2008 Nov;62(6):1085-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
  • BACKGROUND: Addition of carboplatin (C) to trastuzumab (T) and paclitaxel (P) improves the efficacy in HER2+ metastatic breast cancer (MBC).
  • The primary endpoint was: objective response rate (ORR), and secondary endpoints were: time to progression (TTP), overall survival (OS), and toxicity profile.
  • RESULTS: Forty-one patients (pts) were enrolled-median age: 54.5 years (range 29-75); 87.8% PS 0 or 1; 39 (97.5%) had received prior adjuvant or neoadjuvant treatment; 11 (27%) had received one prior CT line for metastatic disease; disease sites: liver (40%), bone (32.5%), lymph nodes (32.5%) and lung (20%); 19 (47.5%) had > or =2 lesions and 97.5% had measurable disease.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease Progression. Female. Gastrointestinal Diseases / chemically induced. Half-Life. Hematologic Diseases / chemically induced. Humans. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peripheral Nervous System Diseases / chemically induced. Survival Analysis. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365200.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


61. Estrada-Sánchez G, Ochoa-Carrillo FJ, Altamirano-Ley J: [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer]. Cir Cir; 2008 Jul-Aug;76(4):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(18)FDG PET/CT imaging in primary breast lymphoma and breast cancer].
  • BACKGROUND: Of women between 15 and 29 years of age, 13.6% will die from breast cancer.
  • For women between 30 and 64 years of age, 19% will die from breast cancer.
  • METHODS: We studied 1728 oncological patients and 295 patients were included, 293 with breast cancer (17%) and two patients with primary breast lymphoma (0.1%).
  • SUVmax for the primary tumor was 4.2 +/- 2.6 SD.
  • Mean SUVmax for patients with primary breast lymphoma were 3.2 and 1.4.
  • Sites of metastases were lymph nodes in the neck (4.4% SUVmax 2.7), internal mammary lymph nodes (5% SUVmax 5.3), mediastinum (8.3% SUVmax 5.0), retroperitoneal (6 % SUVmax 5.4), ipsilateral axilla (94% SUVmax 4.5), contralateral axilla (4.4% SUVmax 2.8), pectoral muscle (10.2% SUVmax 2.6), pleura (4.4% SUVmax 3.9), lung (32.3% SUVmax 2.9), liver (19.1% SUVmax 4.5), bone (36.7%), adrenal gland (4.4% SUVmax 2.4), brain (4.4%), spleen and contralateral breast, one case each.
  • The incidence of a second primary was 4.7%, 2.1% ovarian, 1.4% lung, 0.3% lymphoma, 0.3% endometrium, 0.3% pancreas and 0.3% thyroid.
  • CONCLUSIONS: Mean SUVmax for the primary tumor was similar to that reported in the literature.
  • [MeSH-minor] Adult. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Brain Neoplasms / radiography. Brain Neoplasms / radionuclide imaging. Brain Neoplasms / secondary. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / radionuclide imaging. Cost-Benefit Analysis. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Hyperplasia. Lymphatic Metastasis / radiography. Lymphatic Metastasis / radionuclide imaging. Lymphoma, Non-Hodgkin / radiography. Lymphoma, Non-Hodgkin / radionuclide imaging. Male. Mammography. Neoplasms, Multiple Primary / radiography. Neoplasms, Multiple Primary / radionuclide imaging. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Thymus Gland / pathology. Thymus Gland / radionuclide imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778536.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Lin XJ, Zheng Y, Xu L, Wan YL: [Experience of radiofrequency ablation on liver malignancies: a report of 803 cases]. Zhonghua Wai Ke Za Zhi; 2007 Nov 1;45(21):1469-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience of radiofrequency ablation on liver malignancies: a report of 803 cases].
  • OBJECTIVE: To summarize the 8-year experience of radiofrequency ablation (RFA) on liver malignancies and explore the effect and prognostic factors.
  • METHODS: From August 1999 to February 2007, 803 patients with liver malignancies, among which there were 672 with primary liver cancer (PLC) and 131 with liver metastasis, were treated with RFA.
  • RESULTS: In the treatment of all the 803 patients with liver malignancies, the mortality was 0.25%, the rate of severe complications was 0.37%.
  • CONCLUSIONS: RFA is a safe and effective method for liver malignancy, and the tumor size and stage are important prognostic factors.
  • [MeSH-major] Catheter Ablation. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275711.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


63. Larsen LP, Rosenkilde M, Christensen H, Bang N, Bolvig L, Christiansen T, Laurberg S: The value of contrast enhanced ultrasonography in detection of liver metastases from colorectal cancer: a prospective double-blinded study. Eur J Radiol; 2007 May;62(2):302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of contrast enhanced ultrasonography in detection of liver metastases from colorectal cancer: a prospective double-blinded study.
  • OBJECTIVE: To compare sensitivity and specificity of contrast enhanced ultrasonography (CEUS) with conventional ultrasonography (US) in detection of liver metastases in patients with colorectal adenocarcinoma (CRC) in a patient-by-patient analysis.
  • MATERIALS AND METHODS: A prospective study of 461 consecutive patients referred to the Department of Colorectal Surgery, Aarhus University Hospital with primary or local recurrence of CRC.
  • In order to detect possible liver metastases all patients underwent liver US, followed by CEUS by another investigator.
  • RESULTS: Standard of reference found liver metastases in 54 patients (14.8%).
  • Contrast enhanced ultrasonography improved the sensitivity significantly in detection of liver metastases from 0.69 by US to 0.80 (p=0.031).
  • CONCLUSION: Contrast enhanced ultrasonography improves sensitivity in detection of liver metastases in patients with CRC and in nearly half of the cases CEUS found a higher number of metastases than US.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Colorectal Neoplasms / pathology. Contrast Media. Image Enhancement. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Ultrasonography, Interventional
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Double-Blind Method. False Negative Reactions. Female. Follow-Up Studies. Humans. Intraoperative Period. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Research Design. Sensitivity and Specificity. Tomography, X-Ray Computed


64. Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F: Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol; 2009 Feb;50(2):323-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
  • METHODS: The JNK activation, global gene expression, and the status of histone H3 methylations were measured in 31 primary human hepatocellular carcinoma (HCC) samples paired with the adjacent non-cancerous (ANC) tissues.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041150.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA116697; United States / NCI NIH HHS / CA / R01 CA119028; United States / NCI NIH HHS / CA / R01 CA116697; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / 5R01CA119028
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Histones; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 8
  • [Other-IDs] NLM/ NIHMS546011; NLM/ PMC4417500
  •  go-up   go-down


65. Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, McAlindon ME, Lobo AJ, Cross SS, Thomson M: Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut; 2007 Jun;56(6):838-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Prospective clinical, pathological and outcome data of patients with colitis-associated Paris class 0-II and Paris class I ALM treated with EMR (primary end points being colorectal cancer development, resection efficacy, metachronous lesion rates and post-resection recurrence rates) were compared with those of sporadic controls.
  • 170 ALMs, 18 dysplasia-associated lesion masses (DALMs) and 16 cancers were diagnosed.
  • 1675 controls were included from our prospective database of patients without CUC who had undergone EMR for sporadic Paris class 0-II and snare polypectomy of Paris type I lesions from 1998 onwards, and were considered to be at moderate to high lifetime risk of colorectal cancer.
  • No statistically significant differences were observed between the CUC study group and controls with respect to age, sex, median number of colonoscopies per patient, median follow-up duration, post-resection complications, median lesional diameter or interval cancer rates.
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Follow-Up Studies. Humans. Male. Middle Aged. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 [10579969.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1186-92 [16329015.001]
  • [Cites] Int J Oncol. 2000 May;16(5):927-34 [10762628.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2710-9 [11051339.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):367-73 [11315901.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):371-5 [11868011.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Br J Surg. 2002 Mar;89(3):272-82 [11872049.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):333-8 [12196768.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Endoscopy. 2003 Oct;35(10):845-9 [14551863.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2543-9 [14638361.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] Gut. 2004 Feb;53(2):256-60 [14724160.001]
  • [Cites] Gut. 2004 Feb;53(2):284-90 [14724165.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):376-8 [14753220.001]
  • [Cites] Gut. 2004 Mar;53(3):376-80 [14960519.001]
  • [Cites] Gastrointest Endosc. 2004 May;59(6):642-50 [15114306.001]
  • [Cites] Endoscopy. 2004 Jun;36(6):491-8 [15202044.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):534-41 [15224277.001]
  • [Cites] Gut. 2004 Sep;53(9):1334-9 [15306595.001]
  • [Cites] Gut. 2004 Sep;53 Suppl 5:V1-16 [15306569.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Gastroenterology. 1981 Feb;80(2):366-74 [7450425.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Gastroenterology. 1991 May;100(5 Pt 1):1241-8 [2013371.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):934-44 [7926483.001]
  • [Cites] Gut. 1994 Oct;35(10):1419-23 [7959198.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1295-300 [10579970.001]
  • (PMID = 17135310.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1954845
  •  go-up   go-down


66. Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF: Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol; 2005 Feb 7;11(5):700-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoints were the time of recurrence.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Antigen-Presenting Cells. Antigens, Neoplasm. Disease-Free Survival. Female. Humans. Hypersensitivity, Delayed / etiology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655825.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  • [Other-IDs] NLM/ PMC4250742
  •  go-up   go-down


67. Dias-Baruffi M, Stowell SR, Song SC, Arthur CM, Cho M, Rodrigues LC, Montes MA, Rossi MA, James JA, McEver RP, Cummings RD: Differential expression of immunomodulatory galectin-1 in peripheral leukocytes and adult tissues and its cytosolic organization in striated muscle. Glycobiology; 2010 May;20(5):507-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of immunomodulatory galectin-1 in peripheral leukocytes and adult tissues and its cytosolic organization in striated muscle.
  • Galectin-1 (Gal-1) is important in immune function and muscle regeneration, but its expression and localization in adult tissues and primary leukocytes remain unclear.
  • Using alphahGal-1, we found that Gal-1 is expressed in a wide range of porcine tissues, including striated muscle, liver, lung, brain, kidney, spleen, and intestine.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 2001 May;124(2):266-73 [11422204.001]
  • [Cites] Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):207-17 [19309568.001]
  • [Cites] Cell. 1991 Jan 11;64(1):91-7 [1986871.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L154-64 [16951131.001]
  • [Cites] Glycobiology. 2006 Nov;16(11):137R-157R [16840800.001]
  • [Cites] Trends Immunol. 2002 Jun;23(6):313-20 [12072371.001]
  • [Cites] Curr Opin Immunol. 1997 Jun;9(3):358-64 [9203409.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2008 Jan;40(1):85-90 [18180857.001]
  • [Cites] Eur Respir J Suppl. 2003 Sep;44:20s-21s [14582895.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5549-62 [15556936.001]
  • [Cites] Nat Med. 2005 Jan;11(1):85-9 [15619631.001]
  • [Cites] Nat Rev Immunol. 2006 Mar;6(3):173-82 [16498448.001]
  • [Cites] FEMS Immunol Med Microbiol. 2009 Jan;55(1):85-92 [19076220.001]
  • [Cites] J Leukoc Biol. 2008 Jun;83(6):1459-66 [18372340.001]
  • [Cites] Blood. 2007 Jan 1;109(1):219-27 [16940423.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):355-66 [11839787.001]
  • [Cites] J Immunol. 1996 May 15;156(10):4018-26 [8621944.001]
  • [Cites] Arch Biochem Biophys. 1993 Jan;300(1):6-17 [8380972.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):57-71 [17321195.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] J Biochem. 1996 Nov;120(5):1007-19 [8982870.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3010-21 [8874199.001]
  • [Cites] FASEB J. 2008 Mar;22(3):682-90 [17965266.001]
  • [Cites] Dev Growth Differ. 2009 Sep;51(7):607-15 [19712265.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5207-12 [7890631.001]
  • [Cites] Glycoconj J. 2004;19(7-9):499-506 [14758073.001]
  • [Cites] Development. 1992 May;115(1):143-55 [1638977.001]
  • [Cites] Glycobiology. 2002 Mar;12(3):199-208 [11971864.001]
  • [Cites] Glycoconj J. 1995 Feb;12(1):63-8 [7795414.001]
  • [Cites] Nat Rev Immunol. 2005 Feb;5(2):101-11 [15662368.001]
  • [Cites] Mediators Inflamm. 1995;4(4):263-9 [18475649.001]
  • [Cites] Int J Biochem. 1990;22(12):1379-85 [2276412.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1505-15 [14507657.001]
  • [Cites] J Biol Chem. 1989 Jan 15;264(2):1310-6 [2910856.001]
  • [Cites] Dev Dyn. 2007 Apr;236(4):1014-24 [17366633.001]
  • [Cites] Arch Biochem Biophys. 2008 Oct 1;478(1):18-25 [18662664.001]
  • [Cites] Nat Med. 2007 Dec;13(12):1450-7 [18026113.001]
  • [Cites] Glycobiology. 2008 Nov;18(11):842-50 [18723690.001]
  • [Cites] Glycoconj J. 2009 Apr;26(3):277-83 [18763034.001]
  • [Cites] Stem Cells. 2006 Aug;24(8):1879-91 [16675596.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):209-31 [12223271.001]
  • [Cites] J Biol Chem. 2008 Jul 18;283(29):20547-59 [18456665.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10601-6 [1375225.001]
  • [Cites] J Cell Biol. 1991 Dec;115(5):1437-48 [1955484.001]
  • [Cites] Development. 1993 Dec;119(4):1229-36 [8306885.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):10109-23 [18216021.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2058-65 [17110462.001]
  • [Cites] Nat Immunol. 2009 Sep;10(9):981-91 [19668220.001]
  • [Cites] J Autoimmun. 1999 Feb;12(1):43-9 [10028021.001]
  • [Cites] Glycoconj J. 2004;19(7-9):615-9 [14758087.001]
  • [Cites] Immunol Rev. 2009 Jul;230(1):172-87 [19594636.001]
  • [Cites] Clin Immunol. 2000 Nov;97(2):79-88 [11027447.001]
  • [Cites] J Pathol. 2004 Dec;204(5):511-8 [15538736.001]
  • [Cites] J Neurochem. 1992 Jan;58(1):200-3 [1309234.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41282-93 [12853445.001]
  • [Cites] Histopathology. 2008 Mar;52(4):483-93 [18315601.001]
  • [Cites] Folia Biol (Praha). 2007;53(4):109-28 [17706016.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):29-41 [15630413.001]
  • [Cites] Cell Tissue Res. 1990 Jan;259(1):43-9 [2297785.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jan 23;378(4):750-4 [19071088.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):218-24 [11834519.001]
  • [Cites] Arch Biochem Biophys. 1989 Nov 1;274(2):404-16 [2802618.001]
  • [Cites] Immunol Rev. 2003 Jun;193:101-10 [12752675.001]
  • [Cites] Crit Care Med. 2007 Sep;35(9):2176-85 [17855834.001]
  • [Cites] Arch Biochem Biophys. 1992 Aug 15;297(1):132-8 [1386213.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3091-102 [18292532.001]
  • [Cites] J Mol Biol. 2004 Oct 29;343(4):957-70 [15476813.001]
  • [Cites] Glycobiology. 2004 Feb;14(2):157-67 [14576172.001]
  • (PMID = 20053628.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL085607; United States / NIAMS NIH HHS / AR / P30 AR053483; United States / NIGMS NIH HHS / GM / T32 GM008169; United States / NHLBI NIH HHS / HL / HL085607
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Galectin 1
  • [Other-IDs] NLM/ PMC2900886
  •  go-up   go-down


68. Jersenius U, Granath F, Arvidsson D, Blomqvist P: Liver operations in Sweden in 1987-99. Scand J Surg; 2005;94(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver operations in Sweden in 1987-99.
  • BACKGROUND AND AIMS: Liver surgery is developing with new techniques and treatment modalities.
  • The aim of this study is to describe liver surgery over a long period of time in a country with a public health care system.
  • PATIENTS AND METHOD: A register study including adult patients admitted for liver resection in Sweden (population 8.8 million) selected from the Inpatient Register 1987-99.
  • Additional data were collected from the Swedish Cancer Register and the Cause of Death Register.
  • The 5-year survival after an operation for primary liver cancer and colorectal liver metastases was 27% and 26%, respectively.
  • CONCLUSIONS: Few patients were admitted for liver operations compared to expected figures.
  • With an increasing awareness of the relatively favourable prognosis and the introduction of new methods, the volume of liver operations will probably increase in Sweden.
  • [MeSH-major] Liver / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Digestive System Surgical Procedures / methods. Female. Humans. Male. Mastectomy, Segmental. Middle Aged. Registries / statistics & numerical data. Survival Analysis. Survival Rate. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865112.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Poultsides G, Brown M, Orlando R 3rd: Hand-assisted laparoscopic management of liver tumors. Surg Endosc; 2007 Aug;21(8):1275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopic management of liver tumors.
  • BACKGROUND: Laparoscopy has clearly advanced the treatment of many diseases related to the liver and biliary tree.
  • The addition of hand assistance can further facilitate minimally invasive liver surgery by providing tactile feedback, atraumatic and versatile retraction, finger-fracture parenchyma dissection, and more precise placement of probes and staplers.
  • METHODS: Over a 7-year period, 28 patients with liver tumors underwent 31 hand-assisted laparoscopic operations at a tertiary care center.
  • The candidates for hand-assisted laparoscopic resection were patients with lesions involving two hepatic segments or fewer located at the inferior edge of the liver (segments 5 and 6), or confined to the left lateral segment (segments 2 and 3).
  • A total of 19 patients (68%) had metastatic disease, and 3 (11%) had primary liver cancer.
  • A group of 15 patients who had metastatic colorectal cancer treated with resection and/or ablation had a mean follow-up period of 24 months (range, 2-61 months) and a mean survival time of 36 months.
  • CONCLUSIONS: For selected patients, the hand-assisted technique can be applied safely and effectively to laparoscopic liver surgery and may identify the presence of previously undetectable intrahepatic or extrahepatic disease.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laparoendosc Surg. 1996 Mar;6 Suppl 1:S61-3 [8832930.001]
  • [Cites] Surg Endosc. 1995 Jun;9(6):733-5 [7482177.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):451-62 [15062655.001]
  • [Cites] Arch Surg. 2002 Apr;137(4):407-11; discussion 412 [11926943.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1363 [12235510.001]
  • [Cites] Br J Surg. 1993 Dec;80(12 ):1571-4 [8298929.001]
  • [Cites] Surg Endosc. 1996 Jul;10(7):758-61 [8662435.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):93-100 [9208969.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] Arch Surg. 1999 May;134(5):477-85; discussion 485-6 [10323419.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):34-43 [10631360.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):854-9 [10896382.001]
  • [Cites] Arch Surg. 1997 May;132(5):505-10; discussion 511 [9161393.001]
  • [Cites] Ann Surg. 2000 May;231(5):715-23 [10767793.001]
  • (PMID = 17479339.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist; 2010;15(12):1310-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
  • BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).
  • The primary endpoint was to determine the disease control rate (DCR) as measured by the Response Evaluation Criteria in Solid Tumors (complete response, partial response [PR], and stable disease) at 6 weeks.
  • CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):193-8 [19047305.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1439-47 [9849429.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1873-82 [19276273.001]
  • [Cites] Oncology. 2009;76(4):254-61 [19246950.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Curr Drug Metab. 2009 Jun;10(5):470-81 [19689244.001]
  • [Cites] J Gastrointest Cancer. 2009;40(1-2):1-9 [19513861.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85 [19828009.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7 [20130876.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:69-73 [10436789.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39 [15648955.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):369-75 [16012797.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]
  • [Cites] BMC Cancer. 2008;8:82 [18373843.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2046-52 [18756532.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166 [11992800.001]
  • (PMID = 21148613.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00397787
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227926
  •  go-up   go-down


71. Méndez Romero A, Wunderink W, van Os RM, Nowak PJ, Heijmen BJ, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC: Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors.
  • PURPOSE: Stereotactic body radiation therapy (SBRT) provides a high local control rate for primary and metastatic liver tumors.
  • This is the first report of quality of life associated with liver SBRT.
  • METHODS AND MATERIALS: From October 2002 to March 2007, a total of 28 patients not suitable for other local treatments and with Karnofsky performance status of at least 80% were entered in a Phase I-II study of SBRT for liver tumors.
  • Two generic quality of life instruments were investigated, EuroQol-5D (EQ-5D) and EuroQoL-Visual Analogue Scale (EQ-5D VAS), in addition to a disease-specific questionnaire, the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30).
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Quality of Life. Stereotaxic Techniques
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Prospective Studies. Surveys and Questionnaires / standards

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996394.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Shah I, Sefvan O, Luqman U, Ibrahim W, Mehmood S, Alamgir W: Clinical stage of oral cancer patients at the time of initial diagnosis. J Ayub Med Coll Abbottabad; 2010 Jul-Sep;22(3):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage of oral cancer patients at the time of initial diagnosis.
  • BACKGROUND: Squamous cell carcinoma is the most common oral cancer.
  • Late diagnosis is however common around the world and contributes to the high morbidity and mortality related to oral cancer.
  • The objective of this study was to determine the clinical stage of oral cancer patients at the time of diagnosis.
  • METHODS: This retrospective study was carried out on 334 oral cancer patients who presented to the outdoor departments of Armed Forces Institute of Dentistry, and Armed Forces Institute of Pathology, Rawalpindi from July 2008 to December 2009.
  • OPG and CT scans of the head and neck region, chest X-rays, abdominal ultrasounds and liver function tests.
  • Size of the primary tumour, the size, number and laterality of the involved cervical lymph nodes and the presence/absence of distant metastases were documented and statistically analysed using SPSS-17.
  • The primary tumour was 4 Cm or more in size, (T3/T4) 71.25% of the cases.
  • CONCLUSION: Oral cancers are diagnosed late (Stage III and IV) in Pakistan and need immediate public and professional attention.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Imaging. Female. Humans. Liver Function Tests. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22338419.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


73. Feng YL, Ling CQ, Chen Z, Li B, Gu W: [Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):844-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient].
  • OBJECTIVE: To observe the protective effect of ginsenosides (GS) or low dose of glucocorticoid dexamethasone (Dex) alone or combined in managing the liver injury and renal function after transcatheter arterial chemoembolization (TACE).
  • METHODS: 120 patients with primary liver carcinoma were randomly divided into four groups (A, B, C, D) with 30 patients in each.
  • The changes in liver and renal function after TACE were observe according to the WHO criteria for side effects of anti-cancer drug.
  • RESULTS: Compared with group A, Dex combined with GS was able to reduce the level of TB, ALT/AST, BUN and Child-grade, which significantly protected the liver and kidney (P < 0. 05).
  • However, Dex or GS alone could also improve some parameters of liver and renal function after TACE (P < 0.05).
  • CONCLUSION: Dex combined with GS is effective in managing the liver injury and renal function after transcatheter arterial
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Dexamethasone / therapeutic use. Ginsenosides / therapeutic use. Kidney / drug effects. Liver Diseases / prevention & control. Liver Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Bilirubin / blood. Blood Urea Nitrogen. Creatinine / blood. Drug Therapy, Combination. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Glucocorticoids / pharmacology. Glucocorticoids / therapeutic use. Humans. Iodized Oil / administration & dosage. Male. Middle Aged. Prospective Studies. Topotecan / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416007.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ginsenosides; 0 / Glucocorticoids; 3Z8479ZZ5X / Epirubicin; 7M7YKX2N15 / Topotecan; 7S5I7G3JQL / Dexamethasone; 8001-40-9 / Iodized Oil; AYI8EX34EU / Creatinine; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; RFM9X3LJ49 / Bilirubin; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Clements D, Dhruva Rao P, Ramanathan D, Adams R, Maughan TS, Davies MM: Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis; 2009 Oct;11(8):845-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
  • OBJECTIVE: The management of the asymptomatic primary in stage IV colorectal cancer presents a dilemma.
  • Nonresectional management of the primary is associated with the risks of obstruction, perforation or haemorrhage.
  • We reviewed our nonoperatively managed patients with colorectal liver metastases in order to identify the percentage of patients requiring urgent operative interventions for symptoms related to the primary.
  • There were no similarities between these three patients in terms of age, sex, site or stage of primary, volume of liver metastases, and alkaline phosphatase (ALP) or carcinoembryonic antigen (CEA) levels.
  • CONCLUSION: Of 37 patients initially treated palliatively for stage IV colorectal cancer, 92% required no surgical treatment of their primary.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis


76. de Santibañes E, Fernandez D, Vaccaro C, Quintana GO, Bonadeo F, Pekolj J, Bonofiglio C, Molmenti E: Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. World J Surg; 2010 Sep;34(9):2133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.
  • BACKGROUND: We evaluated the simultaneous resection of colorectal malignancies and synchronous liver metastases.
  • In all, 185 (25%) of them underwent simultaneous resection of the hepatic lesions and the corresponding primary tumors.
  • CONCLUSIONS: The simultaneous resection of colorectal malignancies and synchronous liver metastases is safe, avoids an additional intervention, can be performed with low morbidity and mortality, and is associated with good oncologic outcomes.
  • [MeSH-major] Colectomy. Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / analysis. Female. Humans. Length of Stay. Male. Middle Aged. Patient Selection. Prognosis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Apr;35(4):926-7; author reply 928 [20981543.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):938-46 [9060531.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Ann Ital Chir. 1996 Nov-Dec;67(6):761-5 [9214268.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] HPB Surg. 1993;6(3):199-203; discussion 203-4 [8387809.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Am J Surg. 1997 Jun;173(6):467-71 [9207156.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):196-202 [12168966.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10 Suppl):S78-84 [11052482.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S35-41 [17981428.001]
  • [Cites] J Surg Oncol. 2001 Sep;78(1):17-21 [11519063.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):129-31 [17256808.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1269-76 [17318552.001]
  • [Cites] Ann Surg. 1997 Nov;226(5):582-6 [9389391.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):872-8 [16671066.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):476-84 [12006929.001]
  • [Cites] Coll Antropol. 2000 Dec;24(2):381-90 [11216406.001]
  • [Cites] Surgery. 2004 Sep;136(3):650-9 [15349115.001]
  • [Cites] Eur J Surg Oncol. 1990 Aug;16(4):360-5 [2379594.001]
  • [Cites] Arch Surg. 2000 Apr;135(4):473-9; discussion 479-80 [10768715.001]
  • [Cites] Semin Oncol. 1991 Aug;18(4):399-406 [1650502.001]
  • [Cites] Arch Surg. 1997 Feb;132(2):115-9 [9041911.001]
  • [Cites] Dis Colon Rectum. 1996 Apr;39(4):429-34 [8878504.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1269-84 [15484340.001]
  • [Cites] J Surg Oncol. 2005 Nov 1;92(2):124-9 [16231370.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):195-201 [17080238.001]
  • [Cites] Ann Chir. 1996;50(7):507-12; discussion 13-6 [9035419.001]
  • [Cites] Am Surg. 1997 Jul;63(7):605-10 [9202534.001]
  • [Cites] Surgery. 1988 Mar;103(3):278-88 [3278402.001]
  • [Cites] Colorectal Dis. 2009 Jan;11(1):3-10 [18637099.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1310-6 [15484344.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):332-7 [10201774.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):62-7 [1994607.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1254-62 [8608500.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):88-93 [9808511.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):282-7 [10587184.001]
  • [Cites] Eur J Surg Oncol. 2005 Jun;31(5):506-11 [15922887.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1143-50 [17200913.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):956-62 [12905548.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1006-12; discussion 1013 [17043279.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2059-69 [12775730.001]
  • [Cites] Radiology. 2002 Sep;224(3):748-56 [12202709.001]
  • [Cites] N Engl J Med. 1994 Apr 21;330(16):1136-42 [8133857.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] J Am Coll Surg. 1997 Apr;184(4):413-34 [9100690.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jan;30(1):7-11 [10770561.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):254-60 [7840389.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):158-69 [10100781.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):109-15; discussion 116-7 [12559192.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] Dig Surg. 2008;25(6):430-5 [19212115.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):797-801 [1873704.001]
  • [Cites] Surgery. 1991 Jul;110(1):13-29 [1866690.001]
  • (PMID = 20532766.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


77. Wang B, Tian HQ, Liang GW: [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Mar;29(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer].
  • OBJECTIVE: To observe and compare the quality of life (QOL) and survival time in patients with advanced primary hepatic cancer (PHC) after they have been treated by the combination of ganji recipe and interventional therapy with Fructus Bruceae Oil Emulsion (FBE) or by the trans-hepatic arterial chemical embolization (TACE) adopting Seldinger's technique.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548447.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Plant Oils
  •  go-up   go-down


78. Zhang M, Li B, Yan LN, Yin F, Wen TF, Zeng Y, Zhao JC, Ma YK: Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol; 2008 Feb 28;14(8):1280-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.
  • METHODS: We retrospectively examined a cohort of 150 consecutive primary cadaveric liver transplants with HCC in our center over 6 years.
  • The predictive power of a new model and the model for end stage liver disease was compared by the receiver operating characteristic curve.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Hepatitis B / complications. Hepatitis B / therapy. Liver Neoplasms / etiology. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cell Survival. Cohort Studies. Female. Humans. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies


79. Kinugasa Y, Morishige K, Kamiura S, Tsukamoto Y, Saji F: Parathyroid hormone-related protein-secreting uterine endometrioid adenocarcinoma. Jpn J Clin Oncol; 2006 Feb;36(2):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of parathyroid hormone-related protein (PTHrP)-secreting metastatic uterine endometrioid cancer was made in a 32-year-old Japanese woman with humoral hypercalcemia of malignancy.
  • The primary endometrial cancer had been removed, and the tumor was diagnosed as Grade 1 endometrioid adenocarcinoma with shallow myometrial invasion.
  • Salvage chemotherapy (paclitaxel and calboplatin) was started from 5 months after surgery when recurrent tumors were detected in the peritoneum and liver.
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Immunohistochemistry. Japan

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418186.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


80. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M: Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg; 2006 Jul-Aug;10(7):987-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, the preoperative diagnosis is difficult; liver masses similar to those of HCC, together with moderately elevated serum AFP and CA19-9 levels, are reliable indicators of cHCC-CC.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Oct 15;78(8):1671-6 [8859179.001]
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Radiology. 2004 Jan;230(1):135-41 [14631050.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Hepatology. 1993 Nov;18(5):1090-5 [7693572.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):832-4 [10919041.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1487-90 [12397714.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):37-46 [11223823.001]
  • [Cites] Surg Today. 2002;32(8):742-6 [12181730.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Int J Cancer. 2001 Sep 1;93(5):751-8 [11477591.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):956-64 [7545644.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):989-97 [12170085.001]
  • (PMID = 16843869.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T: Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat; 2010 Oct;17(10):742-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are several established risk factors for intrahepatic cholangiocarcinoma (ICC), namely primary sclerosing cholangitis, fibropolycystic liver disease, parasitic infection, intrahepatic biliary stones and chemical carcinogen exposure.
  • Incident ICC cases were identified by linking the blood-donor database to the records in the population-based cancer registry for the province.
  • Our results suggest that HBV infection and liver inflammation are independently associated with ICC development.
  • [MeSH-major] Cholangiocarcinoma / epidemiology. Hepatitis B, Chronic / complications. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Blood Donors. Cohort Studies. Female. Hepacivirus / pathogenicity. Humans. Japan. Male. Middle Aged. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Blackwell Publishing Ltd.
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):244-50 [16235981.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1211-6 [16938527.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):1016-21 [17324130.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8 [17689296.001]
  • [Cites] World J Gastroenterol. 2008 Jan 28;14(4):632-5 [18203300.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Am J Gastroenterol. 2008 Jul;103(7):1716-20 [18557716.001]
  • [Cites] Hepatology. 2009 Jan;49(1):116-23 [19085911.001]
  • [Cites] Br J Cancer. 2009 Jun 2;100(11):1765-70 [19436294.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2471-7 [10861422.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):959-64 [11808716.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):592-5 [15245596.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2259-62 [15259077.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1075-80 [15386355.001]
  • [Cites] Cancer. 1980 May 15;45(10):2663-9 [6155197.001]
  • [Cites] Vox Sang. 1993;65(3):199-203 [7504373.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Feb;91(2):154-61 [8114321.001]
  • [Cites] Semin Liver Dis. 1994 May;14(2):109-14 [8047893.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):933-40 [8921477.001]
  • [Cites] J Epidemiol. 1998 Dec;8(5):292-6 [9884479.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • (PMID = 20002305.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC3020326
  •  go-up   go-down


82. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC: Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep; 2008 Apr;19(4):1045-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer cells with a high glycolytic rate have an advantage in tumor growth.
  • HKII mRNA was overexpressed in 70 (35%) primary HCCs.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Fructose-Bisphosphate Aldolase / genetics. Hexokinase / genetics. Liver Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Enzymologic. Genes, p53. Humans. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357395.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.1.1 / Hexokinase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


83. Jelski W, Zalewski B, Szmitkowski M: The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer. Dig Dis Sci; 2008 Sep;53(9):2550-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer.
  • BACKGROUND: Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), which are most abundant in the liver, are the main enzymes involved in ethanol and acetaldehyde metabolism.
  • AIMS: The purpose of this study was to compare the activity of ADH isoenzymes and ALDH between liver carcinoma cells and healthy hepatocytes.
  • PATIENTS: Samples were taken from 44 liver cancer patients (19 drinkers, 25 nondrinkers).
  • Seventeen patients had primary liver tumors and 27 had metastatic liver tumors.
  • RESULTS: The activities of total ADH, ALDH, and class I ADH were significantly higher in cancer cells than in healthy tissues.
  • The other tested classes of ADH showed a tendency toward higher activity in cancer than in normal cells.
  • The differences between enzymes of drinkers and nondrinkers in both cancer and healthy tissue, were not significant.
  • CONCLUSION: Differences in the activities of total ADH, ALDH and class I ADH isoenzyme between cancer liver tissues and healthy hepatocytes might be a factor in ethanol metabolism disorders, which can intensify carcinogenesis.
  • [MeSH-major] Alcohol Dehydrogenase / metabolism. Aldehyde Dehydrogenase / metabolism. Aldehyde Oxidoreductases / metabolism. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Biopsy. Case-Control Studies. Female. Humans. Isoenzymes / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Dev Alcohol. 1998;14:7-40 [9751941.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9247-51 [1409630.001]
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):531-5 [17211707.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Alcohol Clin Exp Res. 2001 May;25(5 Suppl ISBRA):137S-143S [11391063.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Ann Clin Biochem. 1993 Mar;30 ( Pt 2):146-51 [8385433.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Histochem Cell Biol. 1999 May;111(5):391-7 [10403118.001]
  • [Cites] Cancer Lett. 1993 Feb;68(2-3):177-83 [8443790.001]
  • [Cites] J Clin Lab Anal. 2003;17(3):93-6 [12696080.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):87-107, vi [11218921.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):1085-105 [8143977.001]
  • [Cites] Alcohol. 2005 Apr;35(3):195-203 [16054981.001]
  • [Cites] Clin Liver Dis. 2005 Feb;9(1):1-35 [15763227.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):69-85 [11218920.001]
  • [Cites] Pancreas. 2007 Aug;35(2):142-6 [17632320.001]
  • [Cites] Carcinogenesis. 1985 Dec;6(12):1683-7 [4064245.001]
  • [Cites] Dig Dis Sci. 2002 Jul;47(7):1554-7 [12141816.001]
  • (PMID = 18224440.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.1.1.1 / alcohol dehydrogenase IV; EC 1.1.1.284 / formaldehyde dehydrogenase (glutathione); EC 1.2.- / Aldehyde Oxidoreductases; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


84. Chen SG, Zhang SM, Zhao HT, Zhang N, Han K, Wang SB, Qu Q, Wei X, Rui J: [Results of multimodality therapy for unresectable primary liver cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):709-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of multimodality therapy for unresectable primary liver cancer].
  • OBJECTIVE: To investigate the therapeutic measures for unresectable primary liver cancer (PLC).
  • METHODS: The date of 312 unresectable primary liver cancer patients treated from January 1991 to March 2003 were retrospectively analyzed.
  • CONCLUSION: Treatment for the unresectable primary liver cancer should be individualized and combined with suitable therapeutic modalities.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Cryosurgery. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274382.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Sheah K, Ouellette HA, Torriani M, Nielsen GP, Kattapuram S, Bredella MA: Metastatic myxoid liposarcomas: imaging and histopathologic findings. Skeletal Radiol; 2008 Mar;37(3):251-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean time from the diagnosis of primary tumor to the first metastasis was 4.4 years.
  • Sixty-seven percent of patients had bone and soft tissue metastases, 33% had pulmonary metastases, 33% had liver metastases, 25% had intra-abdominal, and 16% retroperitoneal metastases.
  • The bones and soft tissues were the most common site of involvement, followed by the lungs and liver.
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2788-93 [10914725.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1514-20 [2776110.001]
  • [Cites] Clin Orthop Relat Res. 1989 Jun;(243):204-7 [2721066.001]
  • [Cites] J Mol Diagn. 2000 Aug;2(3):132-8 [11229517.001]
  • [Cites] Am Surg. 2006 Jan;72(1):68-70 [16494187.001]
  • [Cites] Hinyokika Kiyo. 2006 Sep;52(9):727-31 [17040061.001]
  • [Cites] Sarcoma. 2007;2007:36785 [17641744.001]
  • [Cites] Radiographics. 2005 Sep-Oct;25(5):1371-95 [16160117.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Aug;65(8):1660-4 [17656299.001]
  • [Cites] J Laryngol Otol. 2006 Jun;120(6):511-3 [16563196.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):129-34 [7998525.001]
  • [Cites] Skeletal Radiol. 1990;19(2):113-6 [2321040.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):37-40 [9524706.001]
  • [Cites] J Surg Oncol. 2002 Jun;80(2):89-93 [12173385.001]
  • [Cites] Auris Nasus Larynx. 2004 Dec;31(4):443-6 [15571922.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L185-91 [15018186.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1815-22 [17724681.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3977-87 [11751490.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1507-14 [17252290.001]
  • [Cites] Radiology. 2004 Nov;233(2):493-502 [15459325.001]
  • (PMID = 18097662.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M: Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg; 2007 Oct-Dec;70(4):331-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into 2 groups: diagnosis and staging of primary tumours (n=34) and restaging: screening for recurrent or progressive pancreatic cancer (n=12).
  • Thirty-four lesions were defined as 'definitely pathologic' and localised in pancreas, liver, lung or bone by all 3 techniques with equal certainty.
  • The accuracy rate of PET/CT (91.2%) for diagnosis of primary pancreatic lesions is higher compared to CT (88.2%) and PET alone (82.3%).
  • Fused PET/CT has a slightly higher sensitivity and accuracy rate for diagnosis and locoregional staging of primary pancreatic lesions compared to CT alone.
  • PET and PET/CT perform equally well in screening for recurrent or progressive pancreatic cancer, with high accuracy.
  • Due to its unlimited access, lower radiation exposure and cost, multidetector row CT remains the imaging technique of choice for diagnosis, staging and screening for recurrent pancreatic cancer.
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / diagnosis. Disease Progression. False Positive Reactions. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18330088.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


87. Borie F, Niampa H, Bouvier AM, Faivre J, Launoy G, Delafosse P, Velten M, Buemi A, Peng J, Grosclaude P, Trétarre B: [Current management and prognosis of intrahepatic cholangiocarcinoma in France]. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):971-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate current management and prognosis of ICC in nine French administrative areas, which are covered by population-based cancer registries.
  • METHODS: Between 1997 and 1998, 1100 cases of primary liver cancer were observed in nine French departments: 68 were ICC.
  • The remaining liver was normal in 72% of cases (patients with cirrhosis: 12%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. France / epidemiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant. Registries. Survival Analysis

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647386.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


88. Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG: De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant; 2006 Sep-Oct;20(5):617-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo malignancies following liver transplantation: a case-control study with long-term follow-up.
  • BACKGROUND: Long-term survival data on de novo malignancy are limited following orthotopic liver transplantation (OLT) when compared with controls without malignancies.
  • The clinical characteristics and survival of these patients were retrospectively reviewed and compared with a control cohort of 50 OLT recipients without malignancy matched with the incidence cases by age, year of OLT, sex, and type of liver disease.
  • RESULTS: Chronic hepatitis C, alcohol and primary sclerosing cholangitis were the three leading causes of liver disease.
  • Skin cancer was the most common malignancy (32%), followed by gastrointestinal (21%), including five small bowel tumors, and hematologic malignancies (17%).
  • Patients with skin cancers had survival similar to the controls, but significantly better than non-skin cancers (p = 0.0001).
  • Patients with non-skin cancer after OLT had diminished long-term survival compared with the controls.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl Surg. 1996 Jan;2(1):52-9 [9346628.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1141-50 [9305716.001]
  • [Cites] Transplant Proc. 1995 Feb;27(1):1247 [7878867.001]
  • [Cites] J Hepatol. 2004 May;40(5):728-35 [15094218.001]
  • [Cites] Am J Transplant. 2004 Apr;4(4):596-604 [15023152.001]
  • [Cites] Liver Transpl. 2002 May;8(5):488-90 [12004350.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1237-43 [9740091.001]
  • [Cites] Transplantation. 1998 Nov 15;66(9):1193-200 [9825817.001]
  • [Cites] Liver Transpl. 2002 May;8(5):482-7 [12004349.001]
  • [Cites] Transplantation. 2000 Nov 15;70(9):1335-42 [11087149.001]
  • [Cites] Transplant Proc. 2002 Feb;34(1):297-8 [11959293.001]
  • [Cites] Liver Transpl. 2002 Mar;8(3):285-91 [11910575.001]
  • [Cites] Liver Transpl. 2001 Nov;7(11 Suppl 1):S109-18 [11689783.001]
  • [Cites] Liver Transpl. 2001 Sep;7(9):811-5 [11552217.001]
  • [Cites] Liver Transpl. 2005 Jan;11(1):89-97 [15690541.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1275-7 [10083569.001]
  • [Cites] J Hepatol. 2001 Jan;34(1):84-91 [11211912.001]
  • (PMID = 16968488.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK026743; United States / NIDDK NIH HHS / DK / P30DK26743
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Other-IDs] NLM/ NIHMS582178; NLM/ PMC4050657
  •  go-up   go-down


89. Aslam MI, Kelkar A, Sharpe D, Jameson JS: Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg; 2010;8(4):305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers.
  • INTRODUCTION: Approximately 20% of patients with colorectal cancer have metastases at the time of presentation.
  • Such patients are often offered systemic chemotherapy but debate continues as to whether these patients benefit from resection of the primary tumour.
  • We describe our ten years experience of managing the primary tumours in patients with stage IV colorectal cancer.
  • PATIENTS & METHODS: 920 consecutive patients presenting with stage IV colorectal cancer disease were identified from the Leicester Colorectal Cancer database.
  • Patients undergoing resection of the primary tumour (Resection Group) with the residual metastatic disease were compared to those patients who had not their primary tumour excised (Non-Resection Group).
  • The multivariate analysis of different survival predicting variables, revealed the resection of the primary tumour as an independent predictor of overall survival (p < 0.001).
  • Treatment with post-operative chemotherapy and a smaller volume of liver metastases were associated with prolonged survival (p < 0.05).
  • CONCLUSIONS: Surgical resection of primary tumour for stage IV colorectal cancers is associated with prolonged survival for selected patients.
  • Age at presentation, extent of liver involvement, tumour fixity and ASA grade can help to decide the patients who will benefit from surgery.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Surgical Associates Ltd. All rights reserved.
  • (PMID = 20380899.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Han XJ, Dong BW, Liang P, Yu XL, Yu DJ: [Local cellular immune response induced by ultrasound-guided tumor bed superantigen injection after percutaneous microwave coagulation therapy for liver cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Aug;31(8):602-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local cellular immune response induced by ultrasound-guided tumor bed superantigen injection after percutaneous microwave coagulation therapy for liver cancer].
  • OBJECTIVE: To investigate the local cellular immune response after injection of superantigen, the highly agglutinative staphylococin (HAS), into the tumor bed after ultrasound-guided percutaneous microwave coagulation therapy (PMCT) in the liver cancer patients.
  • METHODS: Ninety-two patients with pathologically proven primary liver cancer were divided into two groups: 45 in group A were treated by PMCT alone and 47 in the group B by combined with ultrasound-guided percutaneous injection of highly agglutinative staphylococin (HAS).
  • CONCLUSION: The local cellular immunity in liver cancer treatment area can be significantly improved by ultrasound-guided injection of highly agglutinative staphylococin after percutaneous microwave coagulation therapy.
  • [MeSH-major] Antigens, CD / immunology. Electrocoagulation / methods. Liver Neoplasms / therapy. Microwaves / therapeutic use. Superantigens / therapeutic use. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD3 / immunology. Antigens, CD4 / immunology. Antigens, CD57 / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021948.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD57; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Superantigens
  •  go-up   go-down


91. Song I, Rhim H, Lim HK, Kim YS, Choi D: Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol; 2009 Nov;19(11):2630-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The technical success rate, as well as the primary and secondary technique success rate, was assessed by regular follow-up CT examinations.
  • The primary technique effectiveness was 85.3%.
  • [MeSH-major] Ascites / pathology. Carcinoma, Hepatocellular / radiotherapy. Catheter Ablation / methods. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Necrosis. Time Factors. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1224-6 [15100123.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):593-600 [11005558.001]
  • [Cites] J Vasc Interv Radiol. 2002 Mar;13(3):313-5 [11875091.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1277-82 [16783759.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):122-30 [16012942.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • [Cites] J Gastroenterol. 2007 Apr;42(4):306-11 [17464460.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] Br J Surg. 2008 Aug;95(8):996-1004 [18581421.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Abdom Imaging. 2009 May-Jun;34(3):371-80 [18463915.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):583-8 [15333339.001]
  • [Cites] Radiology. 2007 Jun;243(3):877-84 [17517940.001]
  • [Cites] Radiology. 2008 Aug;248(2):670-9 [18519740.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Gut. 2005 Aug;54(8):1151-6 [16009687.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Hepatology. 1992 May;15(5):948-63 [1314774.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):817-8 [11222239.001]
  • [Cites] J Vasc Interv Radiol. 2003 Sep;14 (9 Pt 1):1183-6 [14514811.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):428-36 [17639375.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):41-52 [14730035.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1561-2 [12760919.001]
  • [Cites] Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):302-4 [14562984.001]
  • [Cites] Hepatology. 2008 Jan;47(1):82-9 [18008357.001]
  • [Cites] Radiology. 2002 Mar;222(3):819-23 [11867807.001]
  • [Cites] Cancer Treat Rev. 2007 Aug;33(5):437-47 [17512669.001]
  • [Cites] J Gastroenterol. 2003;38(11):1066-70 [14673724.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):197-200 [15208138.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jan;172(1):65-6 [9888741.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jan;190(1):91-8 [18094298.001]
  • [Cites] Radiology. 1999 Mar;210(3):655-61 [10207464.001]
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17 (3):541-7 [16567679.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):103-6 [618417.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):407-10 [15758140.001]
  • (PMID = 19557416.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Malmström A, Hansen J, Malmberg L, Carlsson L, Svensson JH, Ahlgren J, Ahlin C, Jansson T, Westberg R: Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. Acta Oncol; 2010;49(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
  • AIM: The aim of this study was to explore the clinical value of gemcitabine combined with capecitabine (GC) in heavily pre-treated patients with metastatic breast cancer.
  • In 14 patients (41%), more than two metastatic sites were diagnosed with bone (68%) and liver (62%) being the most prominent.
  • The primary objective was to investigate time to progression.
  • DISCUSSIONS: We investigated the value of the GC combination as a treatment for late stage breast cancer patients.
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Humans. Kaplan-Meier Estimate. Middle Aged. Salvage Therapy. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839920.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Neff R, Abdel-Misih R, Khatri J, Dignazio M, Garcia M, Petrelli N, Wilson P: The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. Cancer Invest; 2008 Mar;26(2):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors.
  • The yttrium-90 radiation dose was dependent upon the percentage of tumor involvement of the liver, with a dose modification (reduction) adjusted for macroaggregated albumin (MAA) shunted to the lung.
  • RESULTS: Twenty-one patients underwent twenty-five treatments with SIR microsphere therapy for primary and metastatic liver tumors.
  • CONCLUSIONS: The application of SIR microspheres has been utilized for a variety of liver tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiotherapy. Female. Hepatic Artery / radiation effects. Humans. Male. Microspheres. Middle Aged. Neoplasm, Residual / radiotherapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiotherapy. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259948.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


94. Yamazaki H, Horiuchi K, Takano R, Nagano T, Shimizu M, Kitajima M, Murayama N, Shono F: Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int J Environ Res Public Health; 2010 09;7(9):3406-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study defined a simplified physiologically based pharmacokinetic (PBPK) model for nicotine and its primary metabolite cotinine in humans, based on metabolic parameters determined in vitro using relevant liver microsomes, coefficients derived in silico, physiological parameters derived from the literature, and an established rat PBPK model.
  • Elimination rates of nicotine in vitro were established from data from rat liver microsomes and from human pooled liver microsomes.
  • [MeSH-minor] Administration, Oral. Adult. Animals. Biomarkers / blood. Humans. Male. Microsomes, Liver / metabolism. Models, Animal. Models, Theoretical. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. Cotinine .
  • Hazardous Substances Data Bank. NICOTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pharm Sci. 2004 Aug;22(5):419-25 [15265511.001]
  • [Cites] Toxicol Sci. 2004 Jun;79(2):381-93 [15056818.001]
  • [Cites] Pharm Res. 1988 Oct;5(10):651-4 [3244618.001]
  • [Cites] Toxicol Appl Pharmacol. 1992 Oct;116(2):177-88 [1412462.001]
  • [Cites] Clin Pharmacol Ther. 1993 Mar;53(3):316-23 [8453850.001]
  • [Cites] J Pharmacokinet Biopharm. 1992 Dec;20(6):591-609 [1302764.001]
  • [Cites] Brain Res. 1993 Sep 10;621(2):311-8 [8242344.001]
  • [Cites] Biochem Pharmacol. 1994 Oct 7;48(7):1524-7 [7945454.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:597-613 [8725403.001]
  • [Cites] Arch Toxicol. 1999 Mar;73(2):65-70 [10350185.001]
  • [Cites] Drug Alcohol Depend. 1999 Sep 1;56(2):99-107 [10482401.001]
  • [Cites] J Biol Chem. 1964 Jul;239:2370-8 [14209971.001]
  • [Cites] Pharmacol Rev. 2005 Mar;57(1):79-115 [15734728.001]
  • [Cites] Chem Res Toxicol. 2005 Mar;18(3):403-14 [15777080.001]
  • [Cites] Nicotine Tob Res. 2005 Jun;7(3):343-50 [16085502.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50 [16103423.001]
  • [Cites] Drug Metab Dispos. 2006 Nov;34(11):1803-5 [16896062.001]
  • [Cites] Toxicol Lett. 2007 Sep 10;173(2):101-6 [17716838.001]
  • [Cites] Chem Res Toxicol. 2008 Jan;21(1):70-83 [18052394.001]
  • [Cites] Science. 2008 Feb 15;319(5865):906-7 [18276874.001]
  • [Cites] Clin Pharmacol Ther. 2008 Apr;83(4):531-41 [18305452.001]
  • [Cites] Pharm Res. 2008 Aug;25(8):1891-901 [18483837.001]
  • [Cites] Toxicol Sci. 2008 Dec;106(2):312-8 [18791183.001]
  • [Cites] Handb Exp Pharmacol. 2009;(192):29-60 [19184645.001]
  • [Cites] Xenobiotica. 2009 Mar;39(3):227-35 [19280521.001]
  • [Cites] Eur J Pharmacol. 2009 May 1;609(1-3):88-95 [19285975.001]
  • [Cites] Drug Metab Pharmacokinet. 2009;24(4):404-8 [19745566.001]
  • [Cites] Nicotine Tob Res. 2009 Oct;11(10):1216-25 [19700523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5190-5 [20212132.001]
  • [Cites] Int J Environ Res Public Health. 2010 Jul;7(7):2953-64 [20717551.001]
  • [Cites] Clin Pharmacol Ther. 2001 Jan;69(1):72-8 [11180041.001]
  • [Cites] Pharmacogenetics. 2001 Jun;11(4):317-23 [11434509.001]
  • [Cites] Drug Metab Dispos. 2001 Oct;29(10):1316-24 [11560875.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):542-50 [11602665.001]
  • [Cites] J Pharm Sci. 2002 Jan;91(1):129-56 [11782904.001]
  • [Cites] Protein Expr Purif. 2002 Apr;24(3):329-37 [11922748.001]
  • [Cites] Toxicology. 2003 Feb 1;183(1-3):151-73 [12504349.001]
  • [Cites] Drug Metab Dispos. 1988 Jan-Feb;16(1):125-9 [2894940.001]
  • (PMID = 20948932.001).
  • [ISSN] 1660-4601
  • [Journal-full-title] International journal of environmental research and public health
  • [ISO-abbreviation] Int J Environ Res Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers; 6M3C89ZY6R / Nicotine; K5161X06LL / Cotinine
  • [Other-IDs] NLM/ PMC2954553
  • [Keywords] NOTNLM ; biomonitoring (major topic) / cytochrome P450 (major topic) / human liver microsomes (major topic) / no-observed-adverse-effect level (major topic) / physiologically based biokinetic modeling (major topic) / simulation (major topic)
  •  go-up   go-down


95. Fiaschetti V, Fiori R, Gaspari E, Crusco S, Simonetti G: Mixed hepatoblastoma in a young male adult: a case report and literature review. Case Rep Med; 2010;2010:919457
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed hepatoblastoma in a young male adult: a case report and literature review.
  • Hepatoblastoma (HB) is a rare malignant tumour of the liver and usually occurs in the first three years of life.
  • Most of these tumours arise in the embryo; hence it seems to be unusual that hepatoblastoma occurs in adults and is an exceptional cause of primary malignant liver tumour in adult patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21113306.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2990241
  •  go-up   go-down


96. Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M: Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today; 2005;35(12):1033-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reverse transcription - polymerase chain reaction (RT-PCR) for alpha-fetoprotein (AFP) is used to detect circulating liver cancer cells.
  • The detection of AFP mRNA was significantly correlated with extrahepatic metastasis after primary surgery, and a shorter disease-free survival time (P = 0.0245 each).
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Liver Neoplasms / blood. Neoplasm Recurrence, Local / blood. RNA, Messenger / blood. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Bone Marrow / metabolism. Case-Control Studies. Chi-Square Distribution. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Polymerase Chain Reaction. Prognosis. Prospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1993 Jul;18(1):47-53 [7686879.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):649-53 [8596379.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):415-23; discussion 423-5 [7574923.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1418-25 [7527002.001]
  • [Cites] Arch Surg. 2000 Dec;135(12):1456-9 [11115352.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):527-32 [11179482.001]
  • [Cites] Arch Surg. 2000 Feb;135(2):213-8 [10668884.001]
  • [Cites] Dig Dis Sci. 2000 Jul;45(7):1376-82 [10961717.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1749-56 [1919627.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4021-7 [10632334.001]
  • [Cites] Hepatology. 1990 Oct;12 (4 Pt 1):680-7 [1698703.001]
  • [Cites] Hepatology. 1994 Apr;19(4):889-94 [8138262.001]
  • [Cites] Gastroenterology. 1995 Mar;108(3):768-75 [7875479.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):381-6 [10228826.001]
  • [Cites] Hepatogastroenterology. 1996 Jul-Aug;43(10):919-25 [8884314.001]
  • [Cites] Hepatology. 2002 Apr;35(4):853-60 [11915031.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2772-80 [7954236.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1503-9 [15307868.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):685-9 [1381801.001]
  • [Cites] Ann Surg. 1997 Jul;226(1):43-50 [9242336.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):1064-7 [2556944.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):818-21 [12378622.001]
  • [Cites] Br J Cancer. 1997;76(5):628-33 [9303362.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Apr;16(4):445-51 [11354284.001]
  • [Cites] Br J Cancer. 1997;75(6):928-33 [9062418.001]
  • [Cites] Arch Surg. 2002 Jan;137(1):94-9 [11772225.001]
  • [Cites] Life Sci. 1998;62(21):1973-84 [9619847.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):469-72 [8751199.001]
  • [Cites] Cancer. 1992 Nov 1;70(9):2263-7 [1327495.001]
  • [Cites] Surgery. 2002 Jan;131(1):34-43 [11812961.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):500-4 [11118315.001]
  • [Cites] Langenbecks Arch Surg. 2001 Mar;386(2):118-23 [11374044.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1534-9 [1403032.001]
  • [Cites] Cancer. 1995 May 1;75(9):2214-9 [7536120.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1504-9 [1347253.001]
  • (PMID = 16341483.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down


97. Barker DF, Walraven JM, Ristagno EH, Doll MA, States JC, Hein DW: Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat. Drug Metab Dispos; 2008 Dec;36(12):2445-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Comparison of Nat1 and Nat2 mRNA expression in bladder, colon, liver, and lung of male and female F344 rats detected no significant gender-specific difference.
  • In Sprague-Dawley and F344 rats ranging in age from neonate to mature adult, colon showed a >10-fold increase in Nat2 during the first postnatal month that did not correlate with changes in Nat1.
  • In contrast, Nat2 showed no developmental change in Sprague-Dawley or F344 liver as Nat1 increased modestly.
  • These measures of rat Nat expression confirm that Nat3 expression is negligible and that Nat1 and Nat2 are the primary determinants of arylamine acetylation activity in all tissues tested.